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"The whole is greater than the sum of its parts."
Aristotle
ABSTRACT
The explosion of omics technologies has led to the large volumes of experimental
biological data being produced in laboratories around the world. The experiments
carried out in different biological domains, such as proteomics, genomics, tran-
scriptomics, etc., allow to study biological process or disease only from a certain
aspect without capturing the system as a whole. In order to get a systematic view
on disease, it is necessary to combine these heterogeneous data. This leads to
a growing need for a composition of the reliable integrated disease-specific data
sets that researchers could effectively work with. The large amounts of diverse
data require development of novel data science - based integration and analysis
methods that can help, e.g. to identify which genes are related to disease or which
drugs are toxic for early human development. These methods should provide flex-
ible and effective ways for a description of biological systems at different levels,
aiming to explain how individual heterogeneous data types relate to one another
and to the studied phenotype or condition.
To this moment there has been a lack of the unified data integration method-
ology in the field of biological sciences. In this thesis we adapt two conceptual
pipelines for data integration depending on the study objective and direct relation
of individual data sets to the phenotype of interest. Both multi-staged data inte-
gration and transformation-based data integration use machine learning methods
as core building blocks. However, a choice of one or the other approach highly
depends on the study set up. While multi-staged data integration consists of a
sequential analysis of individual data sets with a consequent combination of the
results, a transformation-based integration involves data transformation into an in-
termediate form, such as a graph. Deep learning methods have gained popularity
in various domains, being applied to learn useful low dimensional representations
of images, text, videos, etc. However, due to the complexity of graph-structured
heterogeneous data, e.g. lack of fixed node ordering or reference point, these
methods cannot be directly applied on the graph data. Graph convolutional net-
works (GCN) are the state-of-the-art deep learning methods specifically devel-
oped for graphs. These methods leverage both information contained in the nodes
and in the relationships between the nodes.
In this dissertation, we describe scenarios of the application of data integration
methods to the practical tasks in computational analysis of biological data and
illustrate how data integration improves understanding of biological processes.
More precisely, we demonstrate how to combine and analyze different types of
biological data in the example of three biological domains: immunology, toxi-
cology, and Alzheimer’s disease. Combining patient’s data related to immune
disease helps to uncover its pathological mechanisms and to find better treatments
in the future. We analyze laboratory data from patients’ skin and blood samples
by combining them with clinical information. Subsequently, we bring together the
results of individual analyses using available domain knowledge to form a more
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systematic view on the disease pathogenesis. Toxicity testing is the process of
defining the harmful effects of the substances for the living organisms. One of its
applications is a safety assessment of drugs or other chemicals for early develop-
ment of a human organism. In this work, we identify groups of toxicants that have
a similar mechanism of actions. Additionally, we develop a classification model
that allows to assess toxic actions of unknown compounds. In the frames of this
work we describe an approach for the integration of the disparate but complemen-
tary heterogeneous data sets related to Alzheimer’s disease into a novel Hetero-
geneous Network-based Alzheimer’s disease-specific data set (HENA). This data
set is based on FAIR standards and aims to provide bioinformatics researchers
the possibility to exploit this unique resource in the context of research related to
Alzheimer’s disease. Additionally, this large heterogeneous graph-structured data
set provides machine learning experts a possibility to benchmark novel methods
for large graphs. We then apply a novel GCN-based method for heterogeneous
graphs to node classification task in HENA to find genes that are potentially asso-
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1. INTRODUCTION
A rapid advance in technology and decreasing production costs led to the increas-
ing amounts of experimental biological data being produced every day in the labo-
ratories across the world. Scientists carrying out these experiments work in differ-
ent omics domains, e.g. proteomics, genomics, transcriptomics, etc. Various types
of experiments allow researchers to understand parts of the functional processes
and disease mechanisms from different angles. The results of such studies are de-
posited in repositories, such as ArrayExpress [1, 2], IntAct [3, 4], ADNI [5], etc.,
designed for storing data sets of specific experimental data type, e.g. gene expres-
sion, protein-protein interactions, etc. The analysis of accumulated data sets of
protein-protein interactions, gene expression and medical imaging have allowed
to discover valuable knowledge about various biological processes, for example,
identification of biomarkers that indicate a pathogenic processes, or pharmaco-
logic responses to a therapeutic intervention [6, 7]. However, these discoveries
provide only partial understanding when considered in isolation. In order to ob-
tain a systematic view on a biological process in an organism, e.g. a disease, these
individual data sets should be combined. The possibility of accessing the knowl-
edge from various biological domains raises the question of how to combine these
large heterogeneous data sets to obtain a meaningful understanding of the biolog-
ical functions of an organism or a pathological mechanism of a disease described
as a whole. One of the challenging tasks is to create a reliable disease-specific data
sets that researchers could effectively work with. To ensure data quality for the
subsequent analysis and reuse, individual data sets should be preprocessed, rigor-
ously filtered, confirmed by experiments using different technologies and follow
FAIR standards [8]. The potential application scenarios for such data sets in-
clude, for example, combination with newly-generated data as a complementary
source, or use as an independent reference data set for the assessment of novel
discoveries. Although modern technological advances allow quantitative studies
of biological processes in different conditions, the way how these heterogeneous
data types relate to one another and to the phenotype of interest still remains not
completely understood. This issue drives the progress to develop and adapt data
science-based methods that aim to integrate these heterogeneous data sets into a
biologically meaningful multi-level analysis pipeline serving to describe biologi-
cal system or a process [9, 10].
There is no unified classification of data integration methodologies in a field of
biological sciences [11–14]. The amount and diversity of experimental, compu-
tational and domain knowledge data together with study setup dictate the choice
of integration pipeline. In this thesis, we have used several integration approaches
and have selected two generalized ones that are partially based on the classifica-
tion proposed by Ritchie et al. [15]. These approaches are based on the relation
of phenotype of interest and individual available data sets and can be applied in
many different biological scenarios. We divide data integration approaches into
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two groups: multi-staged data integration and transformation-based data integra-
tion. Both multi-staged data integration and transformation-based data integration
use data science-based methods as core building blocks to discover relations in the
data that would be difficult to detected otherwise. Multi-staged data integration
implies a sequential analysis of individual data sets with a subsequent combina-
tion of the results and drawing a conclusion using domain knowledge. Depending
on a nature of the relation between the studies data types, various techniques can
be applied to model each type of relations and detect complex patterns in the
data. There is an abundance of methods for regression and classification tasks,
such as linear models [16, 17] or random forest [18], various testing strategies,
e.g. t-test [19] or non-parametric Wilcoxon test [20–22], clustering methods, i.e
k-means [23], that are well-established for the analysis of biomolecular and clini-
cal data. A transformation-based integration involves data transformation into an
intermediate form, such as a graph. While in multi-staged analysis data sets of-
ten come in a form of a numeric matrix accompanied by a categorical meta-data,
where values represent experimental measurements, in transformation-based in-
tegration data is represented as a more complex structures, e.g. heterogeneous
graphs [24], where nodes and edges are described by a set of attributes. Machine
learning methods have became widely used in the biological sciences due to the
possibility to build predictive models without making strong assumptions about
the underlying mechanisms of biological processes [25–27]. Feature selection
and feature engineering steps are often required for the most effective model per-
formance. In the field of graph analytics traditional machine learning approaches
usually rely on hand-crafted features and are limited by their inflexibility and
high computational costs [28–31]. In recent years, deep learning methods have
gained popularity in various domains, being applied to learn useful representa-
tions of images, text, videos, etc. [25, 32, 33]. The application of such models
enables automatic feature extraction. However, due to the complexity of graph-
structured heterogeneous data, e.g. lack of fixed node ordering or reference point,
these methods cannot be directly applied on the graph data. Graph convolutional
networks (GCNs) are the state-of-the-art deep learning methods specifically de-
veloped for graphs [34, 35]. GCNs are a type of neural network architectures
designed to work directly on graphs and leverage their structural information, i.e.
information contained in the relationships between the nodes.
In this thesis, we demonstrate data science-based approaches for integration
and analysis of heterogeneous biological data in the application to emerging prac-
tical tasks. We show how understanding of the biological processes can be im-
proved using data integration-based approaches. A variety of biological processes,
serving as a base for defining physiological state of an organism, are described by
different omics data. A schematic representation of a thesis structure is demon-
strated on Figure 1.
In Chapter 2 we provide description of omics data origins and possible sources
of experimental, computational, and domain knowledge-based biological data
16
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Figure 1. Schematic representation of the thesis structure.
(Figure 1). The availability of the data sets described in this section largely de-
fines the methods for the integration and analysis. In this chapter we also give
an intuition how each data type is related to one another. Given section describes
data types that were used in the case studies described in Chapter 4-6. In Chap-
ter 3 we introduce two major data integration approaches used in this thesis -
transformation-based and multi-staged integration. We then provide the descrip-
tion of the data science methods used in integrative data analyses ranging from
statistical hypothesis testing and supervised learning methods to state-of-the-art
deep learning methods for graphs (Figure 1). These analysis methods are applied
to the data described in Chapter 2. In the following Chapters 4 - 6 we illustrate
how data integration-based analysis can improve the understanding of biological
processes in application to three biological domains: Alzheimer’s disease, toxic-
ity testing and immunology (Figure 1). More specifically, in Chapter 4, based on
Publication I, we introduce an approach for the integration of heterogeneous bio-
logical data sets related to Alzheimer’s disease [36]. It is an age-related neurode-
generative disorder that progresses with age and eventually leads to death. Several
approved drugs are used to reduce the symptoms of Alzheimer’s disease, however,
no current treatments can modify the underlying disease processes. We apply
transformation-based integration, and describe a novel heterogeneous network-
based data set for Alzheimer’s disease (HENA). HENA is comprised of 64 data
sets of six data types originating from nine data sources. These data types include
17
protein-protein interactions, gene co-expression, epistasis, genome-wide associ-
ation studies (GWAS), gene expression in different brain regions, and positive
selection data. HENA aims to provide researchers an opportunity to utilize this
resource in studies related to Alzheimer’s disease, and to allow machine learning
experts to benchmark their methods using this feature-rich large graph data set.
We also demonstrate an application of GCNs to node classification task in HENA
to find genes that are potentially associated with the disease. In Chapter 5, based
on Publication II, we demonstrate how application of multi-staged data integration
concept can shed the light on the mechanism of a complex immune disease. Pso-
riasis is a skin condition causes cells to build up rapidly on the surface of the skin
forming lesions. The mechanisms of this disease are not clearly understood. We
study pathological mechanisms of the disease by combining laboratory data from
patients’ skin and blood samples and clinical information. Subsequently, we bring
together the results of individual analyses using available domain knowledge. The
Chapter 6, based on the Publications III and IV, is dedicated to the improvement
of developmental toxicity testing strategies using multi-staged data integration.
Toxicity testing is the process of defining harmful effects of the chemicals for
the living organisms or cell lines. It serves for the examination, evaluation, and
interpretation of the harmful effects of a substance. One of its applications is a
safety assessment of drugs or other chemicals for early development of a human
organism. Some of the substances can have similar end results while their mode
of action differs. In this work, we identify groups of toxicants that have a similar
mechanism of actions. Additionally, we develop a classification model that allows
to assess toxic actions of unknown compounds.
The major author contributions of the current thesis based on the Publications
I-IV could be summarized as follows:
1. Collection and combination of the heterogeneous data sets in the domain of
Alzheimer’s disease, toxicology and immunology (I-IV).
2. Integration-based data analysis applied to the domain of Alzheimer’s dis-
ease, toxicology and immunology (I-IV).
3. Application of the state-of-the-art graph convolutional networks to the large
heterogeneous graph-structured biological data sets (I).
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2. BIOLOGICAL BACKGROUND
Homo sapiens as a species has around 1014 cells in its body allowing it to function
as a living organism. Throughout the life of the organism cells are dividing and
obtaining their specialization to become, for example, blood cells, muscle cells,
neurons or even cancer cells. The fate of each cell depends on the set of proteins
being produced inside it. It is the proteins that are responsible for the functional
specialization of the cell [37].
The information about human organism is stored in each cell nucleus in the
form of DNA. DNA is a long double stranded molecule that carry genetic in-
formation. The two DNA strands, known as polynucleotides, are composed of
nucleotides. Each nucleotide is formed by one of four nucleobases: adenine (A),
thymine (T), cytosine (C), guanine (G), a sugar molecule deoxyribose, and a phos-
phate molecule. DNA contains a set of instructions for producing proteins, the
building blocks of our bodies. These instructions are inscribed in the structure of
the DNA molecule through a set of functional regions called genes. The instruc-
tions are carried out by the cell’s molecular machinery to produce new proteins
and ultimately regulate functionality and fate of the cell. The flow of information
from genes to proteins is described as follows: DNA is transcribed into RNA,
RNA is translated into protein [38] (Figure 2).
DNA replication 
DNA       DNA
Transcription 
DNA       RNA
Translation 







Figure 2. Flow of information from genes to proteins. Figure illustrates the process
of DNA transcription into RNA and further RNA translation into protein. Individual
coloured bars indicate nucleotide bases. The filled blue circles stand for protein amino
acids.
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Specific types of experiments are designed to catch different aspects of cellu-
lar functioning, e.g. on the DNA (genome), RNA (transcriptome) or protein (pro-
teome) level, and its relation to the phenotype of interest (phenome). For example,
the results of such experiments describe DNA sequence of an individual, detected
mutations in the genome, measured levels of gene expression in different tissues
or protein levels and interactions in various biological conditions, e.g. disease and
healthy. The data sets produced from these experiments form so called omics data
layers. The word omics in the context of this work refers to the set of studies and
methods focused on the data sets of individual origin. In the Section 2.1 and 2.2
we will introduce individual omics layers and biological data types that originate
from experiments and analysis of the corresponding omics data (Figure 3).
2.1. Omics data origins
As organism is a complex system, there is no single layer of information that is
sufficient to completely explain the mechanisms by which genes at genome layer
lead to complex phenotypes at phenome layer (Figure 3). It is the combination
of the individual intermediate layers and their relationship that can bring the sys-
tematic view on how specific phenotype is formed and why [11, 13, 39]. Below
we will describe the most frequently addressed omics data origins and describe












Figure 3. Combining individual omics layers.
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2.1.1. Genome
A genome is a complete set of genetic information in an organism stored in its
DNA. It contains coding regions for producing proteins and non-coding regions,
e.g. regions producing functional RNA-s or RNA-s taking part in transcriptional
and translational regulations [40]. It provides all information that is required for
building and maintaining the organism. The genome is stored in a form of long
DNA molecules tightly packed into chromosomes. The study of genomes, known
as genomics, focuses on sequencing, assembling, and analysing the structure and
function of genomes. Genomics and the corresponding types of data produced
from such studies can be divided into several groups.
Genome sequencing and subsequent mapping of genes and genetic markers to
their locations in the genome provides valuable information. These genetic mark-
ers represent short sequences and individual positions that can be used to identify
individuals or species. An example of such marker is a single nucleotide poly-
morphism (SNP) that is a variation at a single position in a DNA sequence among
individuals. This knowledge can be used to manipulate the genes and DNA seg-
ments of an organism. Another branch of genomic studies, functional genomics,
answers the questions about the relationship between genotype and phenotype on
genome-wide level. It investigates function of DNA at the levels of genes, RNA
transcripts, and gene products and their interactions [41]. Genome-wide associ-
ation study (GWAS) is a comparison of a genome-wide set of genetic variants,
e.g. SNPs, in different individuals to find variants associated with a defined phe-
notype such as human disease, response to treatment, etc. [42]. Also, the joint
effects of genes or genetic variants can produce a completely new trait in com-
parison with the traits in which individual effect of each gene or genetic variant
takes place [43, 44]. Epistasis is an interaction between genes at two or more lo-
cations in the genome when the effect of one gene is dependent on the presence
of the other gene [45]. The studies of epistasis allow to detect interacting genetic
variants determining the trait or phenotype of interest such as disease associated
phenotype. Another direction in genome studies is called comparative genomics.
It is designed to compare the genomes of different organisms, e.g. human, mouse,
chimpanzee, bacteria, etc. The goal of such studies is to find similarities and
differences in sequences, and to identify evolutionary relations between species.
Comparative genomics methods rely on the principle that common features of two
organisms will often be encoded within the DNA that is evolutionary conserved
between them [46, 47]. Data types related to genome level of information are
described in Section 2.2.2.1, 2.2.2.4-2.2.2.5, 2.2.3.2 and 2.2.3.4.
2.1.2. Transcriptome
The total set of messenger RNA (mRNA) molecules expressed by genome is
known as transcriptome. The mRNA carries genetic information copied from
DNA template strand, that is later processed to create a protein. Transcriptome
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describes the set of mRNA transcripts that are specific to some tissue or a par-
ticular cell type both qualitatively, describing what transcripts are present, and
quantitatively, reflecting how much of each transcript is expressed [48]. In other
words transcriptome shows which genes are expressed and to what extent in a
particular tissue of interest.
Unlike genome, excluding mutations, transcriptome varies due to the devel-
opmental or environmental conditions. Transcriptome data includes all the tran-
scripts in the cell or tissue type. It reflects the genes that are expressed, or in other
words turned "ON", in cell at a given condition, e.g. healthy or disease (Figure
4) or time, e.g. early development, stage of disease, etc. Traditionally from the
perspective of central dogma of molecular biology transcriptome was viewed as
an intermediate step between genome and proteome. However, in the recent years
other types of RNA molecules besides protein-coding mRNAs were discovered
that can be dysregulated in the disease condition [49–51]. There are a few widely
used laboratory techniques to measure transcriptomics data in the cell, such as
hybridization microarrays, next generation sequencing methods, qRT-PCR, etc.
The overview of data types obtained in transcriptomics studies are provided in the
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Figure 4. Gene expression in healthy and diseased cells. Figure illustrates the differences
in the gene expression profiles and the variety of gene products (proteins) being produced
in healthy and diseased cell. G1..G4 is short for gene 1..gene 4. ON/OFF state indicates
if the gene is transcribed or not.
2.1.3. Proteome
Besides genetic information it is important to know the types and abundance of the
proteins expressed by the organism. It is also critical to understand what proteins
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are being produced in the cell in a given condition or tissue. The entire set of
proteins produced by an organism, tissue or a cell form a proteome [37].
Proteomics, a study of proteomes, uncovers proteins’ functions and their abil-
ity to physically interact with each other, e.g. forming complexes to execute some
functioning role. Additionally, proteomics studies show that functionality of a
protein is dependent of its 3D structure and modifications such as phosphoryla-
tion, lipidation, etc., that take place after translation [52, 53].
In essence, proteome is an expression of an organism’s genome. In contrast
with genome that consists of four nucleotides and is the same in every cell of
the organism, proteome is comprised of twenty different amino acids and various
post-translational modifications. The post-translational modification is an attach-
ment or removal of chemical groups, e.g. sugars, phosphates, etc., to the protein
molecules. The modifications in protein 3D structure allows it to physically inter-
act or not interact with other proteins and protein complexes. The set of proteins
produced by a cell varies depending on cell type, developmental stage, function,
and location in the tissue. Proteome of an organism is constantly changing in
response to various factors including organism’s developmental stage, disease,
and environmental factors. This property of proteome makes it very valuable in
the studies of biological processes and in medical applications. Currently there
are various technologies available in protein research such as mass-spectrometry,
yeast two hybrid assays (Y2H), immunoassays, etc. These technologies allow to
measure, for example, protein abundance and protein-protein physical interactions
(Section 2.2.1.1-2.2.1.2, 2.2.1.6, 2.2.2.6, 2.2.3.1 and 2.2.3.4).
One of the sources for human proteome studies is blood plasma. It contains
information about the proteins being present in the blood. This set of proteins can
serve as an indicator of the physiological state of the body. For example, plasma
contains such types of proteins as cytokines and chemokines involved in immune
system response and inflammation. Thus plasma proteome is a great value for
medical purposes to search for biomarkers in diagnostics and therapeutic use [54].
2.1.4. Phenome
A phenotype is a set of all observable physical and measurable biochemical char-
acteristics describing a given individual, tissue, organism or species. A repertoire
of all phenotypes of a given tissue, organism or species forms phenome [55, 56].
The observable physical characteristics can be represented by height, weight, eyes
color, behaviour, disease state, etc., while biochemical characteristics are, for ex-
ample, levels of hormones or metabolites. A notion of phenotype can be applied to
characterize cell types in the organism. It can be defined as a set of morphological
and additional biochemical characteristics such as expression of the certain genes
or proteins, describing the cell (Figure 4). A phenotype is a physical character-
istic, for example it could be height, weight, behaviour or a blood measurement.
A phenome represents the entire repertoire of all phenotypes of given a given
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tissue, organism or species. Although defining a phenotype for a study depends
largely on a study setup, examples of data types that describe phenome level of
information can be found in Section 2.2.1.5-2.2.1.7, 2.2.1.8.
The phenome is determined by the interplay between organism’s genome and
environmental factors. Knowledge about phenome or in more narrow sense phe-
notypes can be used in medical studies and practices, for example, to under-
stand the etiology of the disease and to foresee how individuals react to thera-
pies [11, 56]. Phenotypic level of information serves as a foundation for medical
and biological studies. It defines the conditions in which the measurements are
taken and analysed. Therefore an outcome of an experiment and a study is highly
determined by how well phenotype of interest is defined. Poorly defined pheno-
types might lead to inability to make right conclusions about studied biological
question, e.g. identify genetic variants, difference in proteins or gene expression
levels, etc.
2.1.5. Other omics
A fast progress in science and technology triggered the expansion and structur-
ing of an existing knowledge. It led to the formation of the new, more specialized,
omics fields. For example, epigenomics studies epigenetic modifications in the or-
ganisms; metabolomics investigates the metabolites present within an organism,
cell, or tissue; metagenomics studies the genetic material containing in environ-
mental samples. The specific data types related to those omics are not included
into the current work.
2.2. Data types
In order to study biological process or an organism at individual omics levels
described Section 2.1 diverse experiments are conducted by scientists working
in different domains. The results of these experiments are data sets of various
types (Figure 3). The development and application of the right data integration
methods are highly dependent on the understanding on how the data were pro-
duced, what was measured and under which conditions. This section provides an
overview of the data types used in the current thesis along with the technologies
used for production and databases used to store data of similar type. Largely all
the data types in bioinformatics studies, and particularly in data integration field,
can be divided into three large groups - experimental, computational and domain
knowledge-based data.
As experimental data we will refer data sets that were obtained in the biolog-
ical laboratories using biotechnological means, e.g. microarray data, qRT-PCR,
Y2H protein interaction data, sequencing data sets, etc. As computational data
we will refer data sets that were obtained as a result of the analysis of the experi-
mental data sets using well-established computational pipelines and methods, e.g.
co-expression, GWAS data sets, positive Darwinian selection, epistasis data, etc.
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Additionally, we will be using the notion of domain knowledge as a collection
of domain expert knowledge and a set of well-established resources such as data
collections and tools for characterization of the findings or for developing a new
hypothesis. For example, we will be using aggregated resources gathering infor-
mation about genes, proteins and biological pathways. A combination of exper-
imental, computational and domain knowledge-based data described in Section
2.2.1, 2.2.2 and 2.2.3 in multi-staged and transformation-based data integration
are later demonstrated in Chapter 4-6.
2.2.1. Experimental data
In this section we will describe experimental data types used in Publications I-IV.
These data types are obtained from studies of individual omics layers described in
Section 2.1. An application of these individual data types are later demonstrated
in the integration setup in Chapter 4-6.
2.2.1.1. Protein-protein interactions
Studying the interacting partners of a protein can reveal its function and provide
information about biological processes it participates in. For example, if most of
the interacting partners of the protein are involved in a given biological process,
there is a chance that the protein of interest is also involved. The process of func-
tion identification can be performed by screening a single protein with a known
function against a set of proteins with unknown function or by scanning a protein
with unknown function against a library of proteins with known function.
The yeast two-hybrid (Y2H) is a well established technique to detect protein-
protein interactions (PPIs) [57]. Y2H relies on the detection of the physical in-
teraction between two proteins. The interaction detection is based on the expres-
sion of so called reporter gene, which is activated when a specific transcription
factor protein binds to its promoter. This transcription factor is comprised of a
DNA-binding domain and an activation domain. In Y2H experiment the protein
of interest, bait, is fused with the binding domain, and the protein library, prey
is fused with the activation domain. The transcription of the reporter gene takes
place only when both prey with activation domain and bait with DNA-binding
domain are present in the promoter and therefore interact [57–61].
Alternative powerful technology for studying PPIs is protein mass spectrom-
etry [62–64]. This method accurately measures mass of different molecules, i.e.
proteins or protein complexes, in a sample. At the first step of process molecules
in a sample are vaporized by heating and then ionized. The ions are sorted based
on their mass-to-charge ratio by analyzer. The detector system catches ions and
records their relative abundance. The advantage of this technology is lack of ne-
cessity to prepare library of proteins. However, mass spectrometry is limited to
detect temporal or weak transient PPIs [65]. Both technologies can be used sepa-
rately or in combination to complement individual results [66, 67]. Additionally,
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gene expression microarrays and RNA sequencing technologies can provide indi-
rect evidence for protein interaction [68]. Aggregated information about protein-
protein interactions (Section 2.2.2.6) collected from various experiments is de-
posited in publicly accessible databases such as IntAct [4], STRING [69,70], etc.
In Chapter 4 we use PPI data in transformation-based study setup of Alzheimer’s
disease. We combine PPI data sets originating from different sources with gene
co-expression (Section 2.2.2.2) and epistasis (Section 2.2.2.5) into heterogeneous
network of interactions to identify genes potentially associated with disease.
2.2.1.2. Protein abundance
Blood plasma is one of the most accessible biofluids that can be used in the clin-
ical diagnostics and for research purposes. Plasma contains variety of proteins
carrying different functions, e.g. regulation of inflammation. The amount of a
protein can be assessed by measuring its concentration, e.g. using Milliplex MAP
multiplex assay [71,72]. This method allows detecting several proteins simultane-
ously [71]. It uses antibodies against several cytokines, i.e., small proteins that im-
mune system uses for communication between cells, to quantify the level of those
cytokines in blood plasma, i.e. blood without red blood cells [73]. Using a case-
control study design, the concentration levels in disease group and healthy group
can be measured and compared. The difference between the levels of concentra-
tions in these conditions can be evaluated using statistical methods, e.g. Wilcoxon
test (Section 3.2.7). The proteins with statistically significant differences in levels
of concentration can potentially serve as biomarkers for the disease [74]. In Chap-
ter 5 we analyze protein concentrations together with gene expression, fluorescent
microscopy and other data sets to study psoriasis pathogenesis using multi-staged
integration approach.
2.2.1.3. Gene expression microarrays
Protein-coding genes in our DNA define what proteins are produced in our body.
An intermediate step of producing a protein is the creation of the DNA transcript
or mRNA molecule. The relations between the mRNA levels and the amount and
the variants of produced proteins are not always so straightforward [75] due to
complex regulatory mechanisms. However, from the practical perspective it is
more convenient to measure the levels of gene expression rather than the amount
of proteins. Gene expression microarray is a high-throughput technology for mea-
suring the expression of thousands of genes simultaneously [76]. Microarrays
are the glass, plastic or silicon plates covered by different short oligonucleotide
sequences called probes. Each of these sequences is a complementary DNA se-
quence to the specific gene [77]. Probes are designed to bind to the unique tran-
scriptome sequences converted to the cDNAs by reverse transcriptase enzyme.
Each microarray can contain thousands of copies of probes corresponding to the
different genes, covering the vast majority of the genes in the organism. Obtained
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cDNAs are labeled with the fluorescent molecules before being introduced to the
slide to bind to the probes. The process of binding is called hybridization.
Quantification of the transcripts of interest is based on measuring the fluores-
cent intensity using a scanner. The intensity signal converted into numeric scale
represents the abundance of the mRNA in the studied sample. There are two types
of microarray technologies - two-channel and single-channel [78]. In two-channel
microarrays two different fluorophores, e.g. Cy3 emitting green color and Cy5,
emitting red color, are used to label the different samples, e.g. cancer and healthy.
The labeled samples are then mixed together for hybridization at the same array.
In the single-channel microarray, e.g Affymetrix Gene Chip, Illumina Bead Chip,
only one fluorophore is used for measuring the signal. When using single-channel
microarray each sample is measured using a separate array.
The limitation of the microarray technology is its dependency on the prior
sequence knowledge. Only the mRNAs with the corresponding cDNA carrying
probes introduced to the slide can be detected. It is not possible to detect the
structural variations for discovering novel genes or transcripts. Detection of the
very similar sequences such as gene isoforms is also limited due to the low sensi-
tivity [79]. However, specifically designed microarrays can be used for those pur-
poses, e.g. to detect single nucleotide polymorphisms and fusion genes [80]. Al-
ternative high-throughput technology that overcomes substantially the limitations
of the microarrays is RNA sequencing (RNA-seq). This method is not dependent
on the defined probes and potentially could be used to detect all mRNA produced
in the cell. However, there might be potential limitations, e.g. in detecting some
low-expressed genes, in case the sequencing depth is not sufficient [81–84]. De-
spite that, gene expression microarray is a robust, relatively low-cost technology
that has been used over two decades. Large collection of publicly reusable gene
expression microarray data is currently deposited at ArrayExpress and Gene Ex-
pression Omnibus databases [1, 2, 85].
High-throughput gene expression data serve as a source for obtaining computa-
tional data types such as gene co-expression and gene differential expression (see
Section 2.2.2.2 and 2.2.2.3 for details). In Chapter 4 and 6 we analyze and com-
bine microarray data sets with other data in application of integration approaches
to two biological domains: Alzheimer’s disease and toxicology.
2.2.1.4. Quantitative real-time PCR
Quantitative real-time polymerase chain reaction (qRT-PCR) is a low-throughput
method used in research and in clinical diagnostics to provide quantitative mea-
surements of gene transcription, i.e RNA abundance in a cell [86, 87]. It is used
for a broad range of applications, e.g. to determine how the expression of a par-
ticular gene changes in the response to alterations in environmental conditions or
various stimuli.
This technology is often used as a gold standard to control or validate the find-
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ings from the experiments that use high-throughput technologies such as gene
expression microarrays. The robustness of the method relies on its ability to ac-
curately amplify known DNA sequences of interest. The amount of an expressed
gene (Section 2.1.2) in a cell can be measured by the number of an RNA transcript
of the gene of interest. To apply qRT-PCR technique to RNA of interest, at the
first step RNA should be converted to the complementary DNA (cDNA). This pro-
cess is performed using reverse transcription, operated by the reverse transriptase
enzyme.
The method relies on the basic principles of the polymerase chain reaction
(PCR) [88]. PCR is a biochemical temperature-based technique to amplify a spe-
cific fragment of target DNA. Amplification process is cyclical, and the amount
of DNA doubles in every cycle. The method consist of three major phases that are
controlled by the change in temperature - denaturation, annealing and elongation
(Figure 5).
Figure 5. Principle of PCR (figure is adapted from Wikipedia [89]). The procedure con-
sists of three parts: denaturation, annealing and elongation. At the denaturation stage the
original double-stranded DNA is "melted" into two single strands at high temperature. At
the annealing stage the temperature is lowered in order to allow DNA primers to bind to
each of the separated strands of the original DNA. At the elongation stage the tempera-
ture is risen again to allow DNA polymerase to add nucleotides to the end of the primer
sequence. The template DNA acts as a reference strand for the polymerase. There are two
copies of the original DNA fragments by the end of the cycle.
The PCR reaction requires a single-strand template. At the denaturation stage
the original double-stranded DNA that needs to be replicated is "melted" into two
single strands at high temperature. Later at the annealing stage the temperature is
lowered in order to allow DNA primers to bind to each of the separated strands
of the original DNA. Primers are short nucleotide sequences complementary to
the gene of interest that serve as a starting point for the complementary DNA
synthesis. At the elongation stage the temperature is risen again to allow DNA
polymerase, i.e a DNA building enzyme, to start adding nucleotides to the end of
the primer sequence annealed to the template DNA. Primers serve as the indicators
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of the direction in which polymerase molecule starts adding the nucleotides. The
template DNA acts as a reference strand for the polymerase [86, 87]. As a result
of such manipulations there are two copies of the original DNA fragments by the
end of the cycle. To quantify the amount of the product in the end of the process
the fluorescent intensity is used. In qRT-PCR the amplified product is measured
at each step of the cycle. Quantification of the RNA can be done in two ways.
A relative quantification approach is applied to calculate the expression levels of
the gene of interest relatively to the expression of the stable reference gene. In an
absolute quantification approach exact produced number of target DNA molecules
is counted [86, 90].
Widely used relative quantification methods measure the difference in expres-
sion level of the gene of interest and the reference gene [91]. Relative quan-
tification is easier to use since it does not require to know in advance the exact
reference amount of the studied gene. However, the crucial aspect when applying
the relative quantification method is the stability of the reference gene [92–94].
The output of the quantification is expressed in the number of cycles, denoted as
CT values. The smaller is the number of cycles, the more gene transcripts were
in the original sample, i.e. the higher is gene expression. Despite being a reliable
method for measuring gene expression, it can be affected by the poor primers de-
sign or reference gene not being stable in a given condition [87, 95, 96]. We use
qRT-PCR gene expression in the study of pathogenesis of psoriasis by identifying
and later comparing expression levels in healthy and disease skin biopsy samples
(Chapter 5). We also study expression of migration-related genes in toxicology
studies to identify mechanisms of action of toxic compounds (Chapter 6).
2.2.1.5. Flow cytometry
Flow cytometry is the technique for the analysis of multiple parameters of individ-
ual cells, such as size and shape, within the heterogeneous population. It is used
in a range of applications, e.g. for cell counting, cell sorting, biomarker detection
and protein engineering. In Chapter 5 used flow-cytometric immunophenotyping
to study changes in T cells subpopulations in psoriasis patients and healthy con-
trol individuals. During the procedure the flow of cells in a stream of a fluid is
passed through a laser beam. The stream of a fluid is used to hydrodynamically
focus the cell mixture through a small nozzle. The flow cytometer captures the
light that is emerged from every cell as it passes the laser beam (Figure 6).
For the detection purpose cells are stained with specific fluorescent molecules
such as fluorophore-labeled antibodies. The generated experimental data can be
visualized as a two-dimensional dot plot. The areas on these plots can be sequen-
tially separated, based on fluorescence intensity. These subsequent extraction of
sub-populations of cells is called gating. Specific gating protocols exist for di-









Figure 6. Schematic diagram of the working principle of the flow cytometry. Heteroge-
neous cell population is stained with fluorophore-labeled antibodies and passed through
a laser beam. The flow cytometer’s detector captures the light that is emerged from a
cell when it passes the laser beam. The generated experimental data can be visualized
as a two-dimensional dot plot. The sub-populations of cells on this plot can be separated
based on fluorescence intensity.
2.2.1.6. Immunofluorescence microscopy
Immunofluorescence microscopy is a very robust and regularly used imaging tech-
nique in research and in medical practices to assess the localization and expression
levels of proteins of interest [99].
It is used for a range of tasks such as immunophenotyping, cell sorting, cell
cycle analysis, etc. The most common application of immunofluorescence mi-
croscopy is immunophenotyping. During this procedure individual populations
of cells in the heterogeneous sample are identified and counted. The cell subsets
are detected by labeling population-specific proteins with a fluorescent tag, known
as fluorophore, on the cell surface. In clinical labs, immunophenotyping is used
for diagnostics purposes [100, 101].
Modern advances in immunofluorescence microscopy allow to use this tech-
nology in broader range of applications, i.e. labeling of structures in living cells
and measuring of the physiological state of a cell [102]. Immunofluorescence can
be used to produce images of tissue sections, cultured cells or individual cells that
are selected by a variety of methods.
2.2.1.7. MINC functional assay
The disruption of cells’ ability to migrate can be used in toxicity testing strategies.
To test if the compounds, e.g. drugs, disturb the migration capacity of neural crest
cells (NCC), migration of neural crest cell (MINC) assay was designed [103]. This
test system assesses, how many cells re-migrate into a cell-free area, i.e. scratch,
within a neural crest cell monolayer after the treatment with the toxic compound.
It is performed by analysing imaging data and counting the number of cells in the
scratch area [103, 104]. While using these assays we can observe the endpoint of
the compound’s action, i.e. if it had an effect or not. This endpoint can indicate
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toxic action of the studied compound, however in order to understand exact mech-
anism of action, MINC assay data should be combined with, for example, gene
expression and known adverse outcome pathway data (Chapter 6).
2.2.1.8. Meta-data about the experiment
Every type of experiment is always accompanied by the corresponding meta-data,
the descriptive information needed for data set to be understood and possibly in-
tegrated with other data sets. Meta-data records contain information about the
purpose of experiment, experimental conditions, phenotypes, protocol, process of
collecting the data, etc. Detailed, well-described and structured meta-data plays
an important role in the tasks of data integration and increases the reproducibility
of research.
2.2.2. Computational data
2.2.2.1. Genome-wide association studies
Genome-wide association studies (GWAS) are hypothesis free methods to identify
genes associated with a phenotype, e.g. a disease.
GWAS examine the genomes to identify the common variants called single
nucleotide polymorphisms (SNPs) in individuals both with and without a common
phenotype, e.g. disease, using genome wide SNP arrays [105,106]. The main goal
of this method is to identify SNPs that are more frequent in people with the disease
than in other individuals. GWAS methods can scan genomes for thousands of
SNPs at the same time to find the genes that can contribute to the person’s risk for
developing a disease, responding to the certain drugs and environmental factors
[42]. GWAS is usually carried out in a case-control experimental setup comparing
two large groups of individuals - case group with a particular phenotype, e.g.
disease, and control group without a particular disease. It aims to identify SNPs
that are more frequently observed in case group in comparison with control group.
During the study both groups are being genotyped where the genetic constitution
of each individual is determined and scanned for the majority of known SNPs.
For each of these SNPs the frequency of each allele, i.e. variant form of a gene,
is counted and compared in case and control groups (Table 2.1). The unit for
reporting effect size in GWAS is the odds ratio between the odds of having a
disease in individuals having a specific allele and the odds of having the disease
for those who do not have the same allele (see equations 2.1) [107–110].
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Where the resulting odds ratios (OR) indicate the following:
OR = 1: no association between genotype and disease
OR > 1: G allele increases risk of disease
OR < 1: T allele increases risk of disease
When odds ratio is higher than 1 then the allele frequency in the case group
is higher than in the control group. Additionally, chi-squared test is used to
test whether the SNP association with the disease is significant [108]. GWAS
approach has proven itself useful in finding genetic variations contributing to
the diseases such as cancer, diabetes, heart disease and neurodegenerative dis-
orders [111, 112].
GWAS detect SNPs and other variants in DNA associated with a phenotype
of interest, e.g. disease, but cannot provide information which genes are causal
[113, 114]. For further studies GWAS results should be combined with other bi-
ological data such as protein-protein interactions to identify the most reliable as-
sociations. These associations can be later link to the proteins and used for the
development of novel drug targets. In Chapter 4 we describe how to incorporate
the results of GWAS studies into the transformation-based data integration and
machine learning model for classification of heterogeneous biological data.
2.2.2.2. Gene co-expression
Gene co-expression describes the correlation between gene expression levels across
multiple samples and biological conditions. Genes that have similar expression
profiles in the same conditions are considered to be co-expressed. This princi-
ple is often used to infer a function of a gene using "guilt-by-association rule"
knowing the function of the group of correlated genes that demonstrate similar
expression patterns [68, 115, 116]. This is based on the idea that genes that are
co-expressed in some biological condition, e.g. cancer, might share a biological
function [117, 118].
Co-expression can be measured using distance metrics such as Euclidean,
Pearson correlation coefficient based, or Spearman rank correlation coefficient
based (see detailed description of metrics and co-expression analysis in Chapter
3. Clustering methods such as k-means (Section 3.2.2.1) and hierarchical cluster-
ing (Section 3.2.2.2) are widely used to find groups of genes with similar expres-
sion patterns using one of the metrics. In Chapters 5 and 6 we demonstrate that
clustering of co-expressed genes followed by functional enrichment analysis and
the combination with domain knowledge about pathways help to understand the
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biological processes these genes are involved in, i.e. psoriasis pathogenesis and
adverse outcome pathways of various toxic compounds.
Co-expression analysis of multiple data sets can reveal more information about
the behavior of the genes [119]. Methods such as Robust Rank Aggregation can
be applied to identify co-expressed genes in a set of microarray experiments [120].
Additionally, in order to illustrate the connection between genomics and pro-
teomics levels of biological evidence, it is important to mention, that gene co-
expression has been used to predict or in some study set-up to validate protein-
protein interactions [115, 121–124]. The main idea is that two genes which have
correlated expression across various multiple conditions are more likely to encode
interacting proteins [65]. These property could be used to identify potentially in-
teracting proteins associated with the disease. However, co-expressed genes may
be unrelated to protein interaction if the genes involved in two different biolog-
ical processes were just activated by the same stimulus. Combination of gene
co-expression with additional data types such as, for example, protein-protein in-
teractions (Section 2.2.1.1), epistasis (Section 2.2.2.5), GWAS (Section 2.2.2.1),
meta data about the tissue where genes are expressed, etc., allows to narrow down
the search space for the potential proteins associated with the disease. In Chapter
4 we combine of co-expression data with other data sets in Alzheimer’s disease
study.
2.2.2.3. Differential expression
In humans and other organisms, nearly all cells contain the same sets of genes,
however, different cells express different sets of genes, i.e have different tran-
scriptomes. These differences in expression are responsible for the properties and
behaviors of the cells and tissues in healthy and disease conditions.
Differentially expressed genes are genes that exhibit statistically significant
change their expression levels between the conditions. These genes can describe
the differences between phenotypes, e.g. healthy and disease, various tissues and
cell types in the organism, indicate the influence of the toxic compounds on early
human development in toxicity testing experiments, etc. In the current thesis we
combine differential expression with other data types in multi-staged integration
setup to study the pathogenesis of psoriasis (Chapter 5) and in toxicology stud-
ies (Chapter 6). Differential expression analysis is commonly performed using
statistical methods such as linear models, ANOVA [16, 17], t-test [19] or non-
parametric Wilcoxon test [20–22]. Statistical tests provide a p-value that serves
as an estimation of a gene being significantly differentially expressed between the
given conditions. The description of the statistical methods is provided in Chapter
3. Additionally, historically the approach known as the fold-change estimation
was applied to identify differentially expressed genes. It evaluates an average
log-ratio of expression values between the samples. In this approach genes are
considered as differentially expressed if fold change is higher than an arbitrary
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cut-off. However, in practice both measures - p-value and fold change are used in
combination to detect the genes with significant changes between conditions.
2.2.2.4. Positive Darwinian selection
Darwinian selection, also known as positive selection, is based on the process of
evolution by means of natural selection where phenotypes with increased chance
of survival have a higher chance to be passed on to the next generations [125]. It
is the process by which advantageous genetic variants propagate in a population.
Understanding the process of adaptation is important for answering many biologi-
cal questions, such as how species respond to environmental changes, e.g. climate
or pathogens, and what mechanisms underlie genetic diseases [126]. Evolution-
ary adaptation occurs when an inheritable change in the phenotype makes it more
preferable in the present environment.
Positive selection studies have contributed to understanding of the evolutionary
basis of diseases such as Alzheimer’s disease [127]. In case of Alzheimer’s dis-
ease several genes were found to be associated with the regulation of transcription
of the selected genes in immune cells, suggesting how disease related molecular
mechanism may have evolved [127]. In Chapter 4 we demonstrate an applica-
tion of positive selection data in transformation-based integration study setup of
Alzheimer’s disease.
The increasing number of completely sequenced genomes of various organ-
isms together with an abundance of bioinformatics methods [125, 128, 129] pro-
vide a possibility to detect events of positive selection by means of compara-
tive genomics. In particular, comparing the genomes from closely related species
have proven to be effective in detecting genetic regions under the positive selec-
tion [130, 131]. Comparative genomics studies identified the genes that might
have experienced positive selection during the evolution of human and other pri-
mates. These genes offer valuable insights for understanding the biological pro-
cesses specific to humans [132]. Comparative genomics relies on the principles
that common features of two organisms will often be encoded within the DNA that
is conserved between the species, i.e. the DNA sequences encoding the proteins
and RNAs responsible for functions that were conserved from the last common
ancestor would be preserved in contemporary genome sequences [133].
Though positive selection cases are of great interest, they are difficult to de-
tect and analyze [125, 134]. Signatures of positive selection can be detected by
using statistical tests like maximum likelihood test, also called branch-site test,
and machine learning algorithms implemented in such tools such as PAML [129],
OmegaPlus [135], SweeD [136].
2.2.2.5. Epistasis
Epistasis can be defined as an effect of interaction between two or more variants
of different genes on a phenotype deviating from their individual effects [45,137].
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In other words, epistasis describes how gene interactions can affect phenotypes
[137]. An effect of the variant in one gene is masked by the presence of specific
variant in another. These interactions are especially interesting in case of complex
traits such as diabetes, multiple sclerosis and Alzheimer’s disease. In Chapter 4
we have used epistatic interactions as one of data layers for the construction of
heterogeneous network-based Alzheimer disease-specific data set.
Epistatic effects are difficult to detect due to the interplay of many factors such
as an increased number of contributing genes and environmental effects. Genes
with epistatic relationships tend to code for proteins that are involved in the same
processes. Looking at epistatic relationships offers clues that help us to understand
how genes and proteins function. The most common way of detecting the epistatic
effects is by using linear regression [137, 138].
2.2.2.6. Aggregated protein-protein interactions
There are different experimental techniques to measure physical interactions be-
tween proteins [139]. The results of the majority of such experiments are reported
in the scientific publications. Several public databases, e.g STRING [69, 70], In-
tAct [3, 4], accumulate data sets from these types of publications and directly
deposited data sets. As a rule in such repositories information about repeatedly
reported interactions is combined and the strength of each interaction is reported
in a form of an aggregated score. Usually along with the aggregated score the
reference to the original publication and the experimental method are mentioned.
One widely used PPI database is IntAct [3, 4]. It is freely available and contains
literature-curated data sets and data sets directly submitted by the users. Addition-
ally, it provides expert-curated data sets, e.g data set of interactions in Alzheimer’s
disease, and computationally selected data sets, e.g. interactions of proteins with
an established role in the presynapse [140] (Chapter 4). The confidence of each in-
teraction in IntAct is reported in a form of a cumulative score normalized between
zero and one across the entire database, where one is of the highest confidence.
The cumulative score depends on the experimental score, detection method, num-
ber of publications and the interaction appeared.
2.2.3. Domain knowledge
Although individual experiments and data analysis provide valuable knowledge
about the disease or biological process that was a subject of a study in a form of
publications, it is important to accumulate and share such knowledge centrally.
This section provides a description about the repositories and databases that serve
for collecting, structuring and aggregating data of similar types.
2.2.3.1. Biological pathways
Genes provide the instructions which proteins should be produced in the cell to
carry out nearly every task in our bodies (Figure 2). Proteins are the building
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blocks of our bodies, they construct our muscles and organs, help our bodies move
and defend us against diseases. Therefore it is important to study and reconstruct
relations between genes and other substances in the cell. As a result of experi-
ments scientists have accumulated knowledge about various types of interactions
between proteins, genes, metabolites and other biological entities. The extracted
knowledge of these interactions is aggregated in a form of biological pathways. It
can describe both the physical and non-physical relations between genes, proteins,
metabolites, etc.
Biological pathways are rather an abstract representation of the biological pro-
cess or a disease in a form of a graph. The vertices in the graphs can represent
various biological entities such as genes, proteins, metabolites, etc. The edges
illustrate the relations between these entities such as chemical reactions, physical
interactions, co-expression, etc.
Biological pathways can be broadly classified into three large groups by their
functional specificity as metabolic pathways, gene regulation pathways and signal
transduction pathways. Metabolic pathways are enzyme-mediated chemical reac-
tions that are involved in either biosynthesis, a formation of new, more complex,
biomolecules or breakdown of them into smaller units. Gene-regulation pathways
describe the relations between the genes that lead to gene activation or inhibition.
Signal transduction pathways show how a chemical or physical signal travels from
a cell’s exterior to its interior. Cells are able to receive various signals through re-
ceptors located on their surface. After interaction with the receptor the signal is
transmitted inside the cell and triggers a particular reaction or process inside the
cell. The knowledge about biological pathways has been gathered, classified and
deposited into the databases such as Kyoto Encyclopedia of Genes and Genomes
(KEGG) [141, 142] and Reactome [143, 144].
Biological pathways are quite often used to represent domain knowledge to
reduce the number of entities in the analysis in the data-driven studies. They are
also used for the characterization of the obtained results according to the func-
tional meaning of the pathway. For example identifying pathways involved in a
particular disease or a part of the pathway that is affected may help to understand
the disease mechanisms and improve diagnostics.
Additionally, to the three groups of biological pathways it is worth mentioning
of a specific novel concept of Adverse Outcome Pathway (AOP) used in toxicity
testing for human risk assessment [145]. An AOP is a schematic representation
of a sequential chain of causally linked biological events that lead to an adverse,
i.e. undesired harmful, effects related to health [10, 145, 146]. An AOP reflects
an existing knowledge about the linked molecular initiating event (MIE) and the
cascade of intermediate or key events (KEs) at the subcellular, cellular, tissue
or organ level that lead to a specific adverse outcome (AO) [10]. AOPs are the
central elements of toxicological studies that are used to support chemical risk
assessment [10].
Biological pathways play an important role in the incorporation of the domain
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knowledge into the analysis and in the interpretation of the results. It is often used
as one of the data sources in multi-staged data integration analysis. We demon-
strate a practical application of the biological pathways in combination with other
computational and experimental data in Chapter 5-6.
2.2.3.2. Aggregated information about genes
Many genes in human and other organisms’ genomes have been studied. As a
result a variety of information was gathered about those genes such as their func-
tions, location in the genome, possible variation, regulation, synonymous names,
related pathways, etc. There are plenty of databases that provide the diverse gene-
centered information such as Ensembl [147, 148], GeneCards [149, 150], Wiki-
genes [151], Entrez Gene [152, 153], etc. Historically various databases were
creating their individual gene names that led to the problem of mapping those
name spaces between each other during the analysis. One of the common prac-
tical problems in bioinformatics analysis is the one-to-many mapping of synony-
mous gene and protein names. Ensembl database currently provides unique uni-
versal identifiers for all genes and transcripts and the possibility of mapping to any
other name space. These identifiers are used by the conversion web tools such as
g:Profiler [154, 155] and David [156].
Gene annotations can help to interpret the analysis results in data driven re-
search or give rise to the new hypothesis. For example, it can provide information
about gene involvement in the disease pathway, its function or location in the
genome.
2.2.3.3. Aggregated information about proteins
Additionally, to the gene-centered information it is important to know the aggre-
gated information about the products that they produce. There are variety of the
protein specific databases such as UniProt [157], HPRD [158], Human Protein
Atlas [159]. These resources collect and provide information about the sequence
of the proteins, their structure, isoforms, post-translational modifications, func-
tion, disease association, expression the different tissues and organs, etc. Protein
annotations constitute another valuable source of information about the biological
process of interest, e.g. disease or response to the certain medication.
2.2.3.4. Gene Ontology
Gene Ontology [160] is a vocabulary-based unified hierarchical representation of
genes and gene products attributes across species. Knowledge about the biological
role of genes and proteins in one organism can often be projected to the other






The biological process, e.g. "regulation of neuron differentiation" is a set of
ordered molecular events [160]. It is characterized by the molecular functions.
Molecular function, e.g."tau protein binding", is a type of biochemical activity
of a gene product [160]. For example, it can include specific binding to ligands
or structures. Cellular component, e.g. "somatodendritic compartment", refers to
the cellular compartment where a gene product carries out its molecular function.
Gene Ontology terms refer to eukaryotic cell structure. Every term has a term
name, e.g. "regulation of neuron differentiation" and a unique term accession
number. Every accession number is represented as a seven digit identifier prefixed
by word "GO:". For example, accession number GO:0045664 corresponds to
the term "regulation of neuron differentiation". Gene Ontology allows functional
interpretation of experimental and computational data using enrichment analysis
(Section 3.2.9).
2.3. Summary
In this chapter we have provided an overview of the biological data types that
were used in the thesis and their origins. We have broadly divided the biological
data into three categories: experimental, computational and domain expert knowl-
edge. We have described the relations between individual data types represented
as individual data layers.
The diversity of computational and experimental biological data requires an
application of appropriate individual data analysis methods and approaches for
the integration of these desperate data types. In Chapter 3 we will describe two
approaches and the corresponding data science methods applied for biological
data integration.
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3. INTEGRATIVE ANALYSIS METHODS
When it comes to biological studies, the variety of experimental, computational
and domain knowledge data dictates the application of the analysis methods suit-
able for the particular data type. Bearing in mind the nature of the relations be-
tween these data types, different machine learning techniques can be applied to
model each type of relations and detect complex patterns in the data. The re-
sults of such individual analyses explain biological process or disease mechanism
at individual levels. The task of integrative data analysis is to combine various
heterogeneous data sets using machine learning methods in an effective way to
discover relations in the data that could not be detected otherwise.
In this chapter we describe data integration approaches and the corresponding
machine learning methods that are used as the building blocks in the analysis. The
methods described in this chapter are applied for the analysis of the biological
experimental data described in the Chapter 2.
3.1. Concepts of data integration in biological sciences
Depending on the study goals and design, data integration task can be approached
in various ways. For example, each individual data set can be analysed separately,
and joint conclusions are later drawn from the results of the individual analyses.
Another way to approach this task is to transform individual data sets together into
the unified data set, i.e. a graph, and subsequently apply analysis methods on the
joint transformed data set. Although there is no universal classification of the data
integration approaches [11–14], in order to ease the reference to these concepts
for the reader we have partially adapted and modified the terminology proposed
in [15]. Thus, we refer to the two approaches described above correspondingly as
multi-staged data integration and transformation-based data integration (Figure 7).
In the following Section 3.2 and 3.3 we provide an intuition about these data in-
tegration approaches and describe corresponding machine learning methods used
in each of them. These methods include unsupervised and supervised classical
machine learning methods applied in multi-staged data integration analysis, and
a set of deep learning methods, graph neural networks, specifically designed for
graph-structured data sets resulting from the transformation-based data integra-
tion.
3.2. Multi-staged data integration
Multi-staged integration is a sequential analysis of the individual data sets using
various machine learning methods. This type of data integration is carried out in
a linear or hierarchical manner, where the analysis is split into multiple steps. In
the case of multi-staged data integration, the original experimental data sets are
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Figure 7. Schematic representation of data integration approaches. Figure illustrates:
a) multi-staged data integration approach; b) transformation-based data integration ap-
proach. The colors of the individual data sets stand for the different data types.
computational data sets that are the derivatives from the original experimental bi-
ological data sets. The resulting computational data sets are then combined to
find associations between different omic types, e.g. using domain-knowledge,
and then interpretation of the result is performed. During the multi-staged data
integration the relation of at most two data types is analyzed separately and then
is associated with the phenotype of interest. This approach sequentially brings
together the results of individual analyses, e.g. differential expression and image
analysis, to capture a deeper knowledge about biological process or disease (Fig-
ure 7 a). The data sets under investigation could be of similar, e.g. a few gene
expression microarray data sets, or different experimental type, e.g. gene expres-
sion, biological pathways, protein concentrations, etc., originating from various
sources. This approach works well when the relation between two data types
could be modelled in a linear manner [15]. In the following Sections 3.2.2 - 3.2.9
we describe methods applied in individual analyses of data types described in Sec-
tion 2.2 to identify relations with a phenotype of interest. These methods are used
as building blocks of the analysis pipeline (see Figure 7 a). Application of multi-
staged data integration approach to the domain of immunology and toxicology is
demonstrated in Chapter 5-6.
3.2.1. Principal component analysis
Measuring the levels of gene expression using various technologies, e.g. microar-
rays or qRT-PCR, has become a standard means for studying biological processes.
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Principal component analysis (PCA) is mostly used as a tool in exploratory data
analysis to visually identify the relationship between the samples in the study. In
case of gene expression analysis PCA is applied to the transposed gene expression
matrix in which columns represent genes and rows represent biological samples.
The visualization of the results, e.g. in the form of scatter plot of a pair of prin-
cipal components, will reflect the grouping of the samples. This type of analysis
can be used to detect the outliers and observe the grouping patterns in the data.
Although PCA can provide an understanding about the separation of biological
samples, this analysis of gene expression data alone will not provide an a system-
atic understanding of a disease. In Chapter 5 and 6 we use PCA for developing
initial understanding about the sample separation that is later accompanied by ad-
ditional analyses. More precisely, in Chapter 5 we apply PCA on gene expression
data obtained from skin biopsy of psoriasis patients and healthy control individu-
als. The results of PCA reveals separation of samples between psoriasis lesional
skin and healthy control skin. However, from this analysis we are not able to infer
the mechanism of psoriasis. In order to obtain more information it is necessary to
combine additional analysis methods and use more data modalities, i.e. to identify
genes that are differentially expressed in disease and control samples, to investi-
gate whether there are changes on protein or cellular level and if these changes
confirm mechanisms investigated on gene expression level.
PCA is a statistical procedure that represents an orthogonal linear transfor-
mation of the original data into a new coordinate system. Individual principal
components (PCs) are uncorrelated linear combinations of original variables as
shown in the equations (3.1) and (3.2) [161]. The first PC y1 can be represented
by the linear combination of the variables x1, x2, ..., xp.
y1 = a11x1 +a12x2 + ...+a1pxp (3.1)
or in a form of a matrix
Y1 = aT1 X (3.2)
The first PC accounts for the greatest possible variance in the data set. It is pos-
sible to make the variance of Y1 as large as possible by increasing the weights
(loadings) a11, a12, ... a1p. In order to prevent this scenario the weights are calcu-





1p = 1 (3.3)
The other PCs are calculated in the similar manner, with the condition that they
should be uncorrelated with the other PCs and that it accounts for the next highest
variance.
As PCA creates a projection of the original data to the new reduced coordinate
system while preserving the most variance in the data, it can be also applied as
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a method for dimensionality reduction before further statistical modeling. Usu-
ally in practice first few components explain most of the variance in the data and
therefore can be used to represent the data without loosing too much information.
Sometimes in gene expression analysis PCA can also be used to identify the
genes that play the most important roles in separation of the samples by the prin-
cipal component. It can be done by observing the loadings vector of the principal
component. The genes with the largest corresponding positive and negative coef-
ficients (loadings) give more impact on the separation of samples by the selected
principal component.
3.2.2. Clustering methods
By analysing gene expression data it is also possible to identify genes that are co-
regulated and might be involved in similar biological processes according to "guilt
by association" rule. Usually these genes have similar expression patterns over
different conditions or phenotypes. Various clustering methods can be applied to
identify such groups of genes.
Clustering methods are unsupervised machine learning methods that allow to
detect groups of similar objects, e.g. gene expression profiles, based on the ap-
plied similarity measure. After genes are grouped based on their expression pat-
terns, these clusters can be characterized using domain knowledge (Chapter 6),
i.e. Gene Ontology [160] and biological pathways from KEGG [141, 142] or Re-
actome [143, 144] databases. Characterization of the gene clusters allows to form
new hypotheses and to understand the role of the particular gene or a group of
genes in a certain biological process or disease (Chapter 5-6). The two most com-
monly used clustering methods are k-means and hierarchical clustering. Below
we explain these methods.
3.2.2.1. K-means clustering
K-means [23] is a clustering algorithm that assumes a predefined number of clus-
ters. On each step the algorithm assigns all data points to the closest cluster center
using defined distance metric. Cluster centers are then recalculated, and the al-
gorithm is repeated until it converges. The initialization can be performed by
assigning cluster centers, e.g. randomly or using specific algorithms, or by initial
partitioning of the data into given number of clusters and assigning the cluster
number to each observation. To perform k-means clustering we need to estimate
the number of clusters beforehand. In general it is not a trivial task. There are
various techniques to select the number of clusters, e.g. based on within cluster
sum of squares that serves as a measure of variability of the observations within
each cluster or based on detection of so-called "anomalous patterns" as the candi-
dates for the initial centroids [162–164]. The results of the k-means clustering is
usually visualized using heatmaps. Heatmap represents a data matrix where the
corresponding values are colour coded. Usually the lowest values correspond to
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the "coldest" colours and the highest values to the "warmest" colours, however,
arbitrary colour scheme can be chosen. Heatmaps allow to visually assess the
trends in the data [165].
3.2.2.2. Hierarchical clustering
The hierarchical clustering method can be used as alternative method for the iden-
tification of patterns in the biological data. In comparison with k-means it does not
require a predefined number of clusters. The result of the hierarchical clustering
is depicted as a dendrogram, that represents a nested tree of partitions [23, 166].
The hierarchical clustering can be built using two main approaches: bottom-
up (agglomerative) and top-down (divisive). In the agglomerative approach the
closest objects are merged on each step of the algorithm to form clusters, and the
distance to the other clusters is recalculated. The algorithm is repeated until one
large cluster is formed. In the divisive approach all the data in a single cluster is
divided into two clusters on each step of the algorithm.
The execution of the algorithm is heavily influenced by the way the distance
between clustered objects is defined and measured. The choice of the distance
metric, e.g. Euclidean, Manhattan, Canberra, correlation, etc., is defined for each
particular task. Euclidean distance (equation 3.4) that measures the absolute dif-
ference between the objects, and correlation distance based on Pearson coefficient


































The way how clusters should be merged is defined by the linkage parame-
ter [23], e.g. in single linkage the clusters with two closest objects are merged, in
the complete linkage the furthest objects are merged, and in Ward’s linkage the
clusters are merged based on the sum of squared deviations to centroids, while
minimizing the within-cluster sum of squares [167, 168]. However, while apply-
ing hierarchical clustering we have to bear in mind the possible uncertainty of
the clustering results due to the statistical sampling error, i.e. when an analysed
sample might not reflect the behaviour of the whole population [169]. In order to
find the most reliable clusters bootstrap resampling techniques, i.e. pvclust, can
be applied [170]. In multi-staged data integration study of psoriasis pathogenesis
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described in Chapter 5 we use hierarchical clustering to identify genes with sim-
ilar expression patterns based on qRT-PCR data. Later these groups of genes are
used to develop a hypothesis about the functions of these groups of genes in the
disease pathogenesis.
3.2.3. Robust rank aggregation
Often it is beneficial to understand the global behaviour of genes in a set of gene
expression microarrays coming from different individual experiments. Gene co-
expression analysis is one of the examples that greatly benefits from the aggre-
gation of multiple data sets, as it can reveal functional relations between the
genes. The results of individual microarray co-expression analyses are the lists
of co-expressed genes that could be ranked based on their co-expression value,
i.e Spearman or Pearson correlation coefficient. In order to understand the global
relations between genes, the results should be aggregated. This integration can be
done using Robust Rank Aggregation (RRA) method [120] as proposed in [119].
RRA is a rank aggregation method based on order statistics. It assumes a defined
baseline model and re-ranks the genes based on the deviation from the baseline
model. The baseline model considers that all input ranked lists would be a random
permutation of the same set of genes. It means that for any gene from the input, its
rank distribution across all list would be uniform. RRA tests the difference of the
given gene rank distribution from the uniform distribution and uses test scores to
re-rank the genes. Genes with observed smaller ranks more often than expected by
the uniform distribution receive lower ranks, meaning that they are ranked in the
top of the resulting list. The underlying probabilistic model makes the algorithm
parameter free and robust to outliers, noise and errors. Test scores also provide a
rigorous way to keep only the statistically relevant genes in the final list. Addi-
tionally, RRA can be applied in other types of meta-analysis of gene expression
data. For example, it can be used for the aggregation of the result of differentially
expressed genes coming from the experiments with the similar objectives.
3.2.4. Linear discriminant analysis
Linear discriminant analysis (LDA) [23,171] is a group of statistical methods used
to find a linear combination of the original variables that separates two or more
classes of objects or events. LDA can be applied to a variety of tasks in biology in
order to classify and define groups of different biological objects. For example, it
can be applied in the toxicology studies to classify the toxic compounds according
to their mode of action. The obtained model can be applied for further mode of
action prediction of unknown toxicants (Chapter 6).
Its purpose is to find the linear combination that gives the best possible sepa-
ration between the groups. The resulting combination (LDA model) may be used
as a linear classifier, or as a method for dimensionality reduction before classifi-
cation, because it attempts to identify the transformation to the lower dimension
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vector space while preserving the class structure of the original space [23, 172].
An optimal transformation, or in other words projection, (equation 3.6) in this case
means the minimization of the within-class variance in the data set and maximizes
the between-class variance simultaneously (equation 3.7) leading to maximum
discrimination [173,174]. LDA computes the directions, i.e. linear discriminants,
that will represent the axes that maximize the separation between the classes.
y =W T x (3.6)






where SB - is between class scatter matrix (a measure of between-class variance),
and SW is within class scatter matrix (a measure of within-class variance).
3.2.5. ANOVA
Often substantial information about the biological process or the disease can be
obtained by studying the change in gene expression or the protein concentrations
in blood plasma. Analysis of these changes helps to identify the difference be-
tween the biological conditions such as the difference between disease patients
and healthy individuals or the difference between various patients’ phenotypes.
It is also used to discover potential disease biomarkers associated with the con-
ditions [175–178]. Analysis of variance (ANOVA) is a method that is frequently
applied by the researchers in clinical studies [175,177–180]. ANOVA is a statisti-
cal method for comparing the means of measurements, such as gene expression or
protein concentration in plasma, in two or more groups. It is based on comparison
of the variability between groups to variability within groups. The groups can be
defined by one or more factors and their categories [181]. For example, in Chapter
5 we apply ANOVA to investigate the difference in gene expression, protein levels
and T cell subpopulations in psoriasis patients with different clinical features, i.e.
duration of the disease that is divided into three groups "less than 10 years", "from
10 to 20 years" and "more than 20 years". While ANOVA shows whether there is
an overall difference between the tested groups, it does not provide information
what exact groups were significantly different. To identify such differences the
post hoc tests for multiple comparisons are applied. Most commonly ANOVA is
followed by Tukey’s honestly significant difference [182].
3.2.6. Linear models for differential expression analysis
Differentially expressed genes (Section 2.2.2.3) exhibit significantly altered gene
expression levels in the compared conditions, e.g. in disease vs. healthy tissue.
They can serve as a potential biomarkers of disease and their characterization can
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provide the hypothesis of the disease origins and mechanism. Differential expres-
sion analysis can be performed using a variety of methods. One of the methods
that can be applied for such tasks is a linear regression model. It attempts to model
the relationship between two or more variables by fitting a linear equation (3.8)
to observed data. In case of the gene expression the main idea is to fit a linear
model to the expression values of a gene. Linear models can be applied in case of
multi-factor design when multiple condition grouping is present.
The method models the distribution of a response variable yi in relation to one
or more explanatory variables xi1, . . . ,xip as follows:
yi = β0 +β1 xi1 + · · ·+βp xip + εi. (3.8)
where yi is a response variable, xi1, ...,xip are one or more explanatory vari-
ables, β0 is a constant(intercept), β1, . . . ,βp are regression coefficients and εi is an
error term.
The linear regression model approach designed specifically for differential
gene expression analysis, taking into account the nature of gene expression data,
is implemented in a widely used software package limma [16]. It was initially
designed for microarray data and later was extended for the application on RNA-
seq data as well. It fits a linear model for each gene for a given series of arrays,
where the coefficients of the model describe the differences between the RNA
sources [183]. However, the method does not treat different genes independently,
instead, information is borrowed between the genes. It is done by modifying gene-
wise variances towards the global variance. This approach reduces the number of
false positives for genes with very small variances and improves the possibility
to detect differentially expressed genes with large variances [16]. In Chapter 6
we identified differentially expressed genes in normal early neural development
and after treatment with toxic compounds, such as well-known anti-epileptic drug
valproic acid. Further combination with PCA and functional enrichment analysis
of differentially expressed genes allowed to characterize the valproic acid MoA
on human cells.
3.2.7. Wilcoxon test
A Wilcoxon rank-sum test (also know as Mann-Whitney-Wilcoxon test) [20, 21,
184, 185] is a non-parametric test, where the test does not assume the samples
(groups) to follow the normal distribution. It is applied to two independent data
samples to test whether their distributions are identical.
Wilcoxon test can be applied in case-control studies to find out if the difference
between measurement, such as the concentration of proteins in plasma or gene
expression in two conditions, e.g. disease and healthy individuals, is significant
(Chapter 5). The case-control studies of gene expression is a widespread case of
a differential expression analysis.
Suppose we have two samples of size n and m from populations X and Y
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with the cumulative distribution functions FX and FY . During the testing proce-
dure original data from two samples are pooled together and transformed into
ranks where the smallest value gets the rank one and the largest rank N = n+m.
Let Z be a vector that indicates the rank-order statistics of the combined samples
and identifies the sample to which each observation belongs: Z = (Z1;Z2; ...;ZN),
where Zi = 1 if the ith random variable in the combined ordered sample originate
from X and Zi = 0 if it originates from Y , for 1,2, ...,N. After that the sum of the
ranks is calculated for both samples as shown in the equation (3.9) [185]. These






We can formulate the null hypothesis that we want to test as both samples come
from the same distribution or formally H0 : FY (x) = FX(x). If the null hypothesis
is true, we would expect a similar mixture of ranks in both samples. The possible
alternative hypotheses can be stated as following: H1 : FY (x) =FX(x−θ). If θ < 0
FY is shifted to the left from FX (X > Y ) and in case θ > 0 then FY is shifted to
the right from FX (X < Y ). In case we consider two-sided case of Wilcoxon test
and formulate our alternative hypothesis as following: H1 : FX 6= FY (X 6= Y ), i.e.
θ 6= 0.
The test can be concluded by calculating the p-values for the Wilcoxon rank-
sum statistic WN as illustrated in Table 3.1 (adapted from [185]).
Table 3.1. Defining p-value for Wilcoxon rank-sum statistic.
Alternative hypothesis p-value
θ < 0 (X > Y ) P(WN ≥ wo)
θ > 0 (X < Y ) P(WN ≤ wo)
θ 6= 0 (X 6= Y ) 2× min{P(WN ≥ wo); P(WN ≤ wo)}
where wo - observed value of WN
3.2.8. Multiple testing correction
When dealing with biological data, often multiple statistical tests are carried out
repeatedly, e.g. to find the differentially expressed genes. The results of such
test are concluded by identifying the cases where the p-value is less than some
given critical value, usually corresponding to 0.05. A p-value of 0.05 means that
there is a 5% chance of getting the observed or more extreme result, when the null
hypothesis is true.
Multiple testing leads to the potential increase of false positive results, i.e.
incorrect rejection of H0 hypothesis. If multiple statistical tests are carried out
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for the data for which null hypothesis holds, then about 5% of them will end up
rejecting the null hypothesis generating false positive results.
Currently there is no generally accepted universal method to deal with the
problem of multiple comparisons. However, a few approaches, e.g. a number of
false discovery rate-based methods [186–190] and Bonferroni correction [191],
are actively used to account for a false positive rate, also known as type I error
[192]. These approaches are known as multiple testing correction procedures.
False discovery rate (FDR) reduction based on Benjamini-Hochberg procedure
[187, 188] is one of the popular methods that controls the expected proportion
of incorrectly rejected null hypotheses in a list of rejected hypotheses. It helps
to lower the number false positives among the significant results. The procedure
converts tests’ p-values into q-values (see algorithm 3.10), i.e. adjusted p-values.
During this procedure original m p-values are ranked in an ascending order, i.e the
smallest rank 1 is assigned to the smallest p-value and rank m to the largest. Then
the q-values are computed using the equation (3.10). These corrected p-values are
then compared with chosen critical value to identify the significant results [193].
qi = min{pi ∗ (m/i);qi+1} f or i = m−1;m−2; ...;1 (3.10)
In equation (3.10) m is the number of tests and i is the rank of the original p-value,
p1...pm are ordered p-values and qm = pm is the largest adjusted p-value.
3.2.9. Functional enrichment analysis
Functional enrichment analysis is applied to characterize a group of genes using
currently available domain knowledge. The aim of this analysis is to identify spe-
cific groups of genes that are over-represented in a large set of genes or proteins,
and may have an association with a studied phenotype, e.g. disease. Often as a
result of bioinformatics analysis, e.g. differential expression analysis, a group of
genes is identified to be connected with the studied biological process or condi-
tion. In order to understand better the underlying biological process and the role
that this set of genes or proteins play in these process, functional profiling of the
gene set is performed. Functional profiling of the selected gene set would reflect
mutual function(s) and the biological processes or pathways where this group of
genes is involved.
Functional enrichment analysis uses Gene Ontology (GO) [160] as the main
source of information about standardized annotation of gene products. Addition-
ally, other databases as KEGG [141, 142], Reactome [143, 144] or The Human
Protein Atlas [194] can be included for characterization.
The analysis is performed by identification of the enriched GO terms or path-
ways in a list of genes. The number of overlapping genes is found between the list
of interest and the reference gene lists corresponding to GO category or pathway.
The significance of the findings is assessed by computing the p-values from Fisher
exact test. The approach is implemented in various tools including web-tools such
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as g:Profiler [155]. In Chapter 6 we demonstrate how functional enrichment anal-
ysis can be applied in toxicology studies as a part of multi-staged data integration
helping to provide more information about the results detected by differential ex-
pression analysis and PCA.
3.3. Transformation-based biological data integration
Currently in the field of omics integration there is an open question what inte-
gration methods should be used to provide flexible and effective way to describe
biological system on the different levels. The answer to this question is highly
dependent on the available omics data sets.
In the transformation-based integration approach multiple data sets are com-
bined after transforming each data set into an intermediate form, such as a graph
[195] or a matrix kernel [196, 197]. Application of kernel-based methods for
omics integration is out of the scope of this work. In the current thesis we focus
on the graph-based transformation methods.
The main idea of this integration technique is a representation of each individ-
ual data set as a graph and further combination of these graphs into one unified
graph. Each individual graph G = (V,E) is described by a set of vertices V , a set
of edges E and an adjacency matrix A. In this graph vi ∈ V denotes a node and
ei j = (vi,v j) ∈ E denotes an edge. The adjacency matrix A is N×N matrix with
Ai j = wi j > 0 if ei j ∈ E and Ai j = 0 if ei j /∈ E [198]. These individual graphs are
constructed from biological omics data sets originating from lab experiments or
computational analysis.
The nodes in these graphs represent biological entities, e.g. genes or proteins,
and the edges depict the type of biological interaction between a pair of nodes,
e.g. co-expression or physical binding between proteins. The nodes and the edges
can carry additional information about the nature of interaction introduced as the
corresponding node and edge attributes, also known as features in the machine
learning terminology (Figure 8). For example, node attributes can be described
by a feature matrix X ∈ RN×D where Xi ∈ RD representing the feature vector of
node vi, N is the number of nodes and D is the number of features.
An example of node attributes can be values describing a level of gene ex-
pression of the node in the disease, its alternative name, biological function, etc.
The edge attributes can reflect information about its direction, type of interaction,
interaction detection method, etc. An edge can also have a weight that describes
some property of the connection between a pair of nodes i and j. For example, an
edge can describe the strength of physical binding between two proteins. For the
purpose of network analysis a set of node or edge attributes can be represented as
a corresponding feature vectors.
The transformed data sets, i.e. individual graphs, can be simultaneously com-
bined constituting a heterogeneous graph (Figure 9) that is described in Section




















a bNode attributes Edge attributes
Figure 8. Example of node and edge attributes. Figure illustrates: a) A set of node
attributes; b) A set of edge attributes.






Figure 9. Combination of individual graphs into unified heterogeneous graph.
munity detection methods or link prediction methods can be applied on the trans-
formed data (Figure 7 b). An advantage of this approach is that it preserves data
type specific properties during the integration process [15]. It can be applied to in-
tegrate many types of data as long as data sets contain a common unifying feature
such as a common gene name, patient identification number, etc.
3.3.1. Heterogeneous graphs
The result of transformation-based integration can be represented as a heteroge-
neous biological graph.
We have adapted the definition of a heterogeneous graph proposed by Lee et
al. [24]. A heterogeneous graph is defined as G=(V,E) consisting of a set of node
objects V and a set of edges E connecting the nodes in G. A heterogeneous graph
50
also has a node type mapping function Θ : V → TV and an edge type mapping
function defined as ξ : E→ TE where TV and TE denote the set of node types and
edge types, respectively. The type of node i is denoted as Θ(i), e.g. a gene, a
protein, or SNP in a heterogeneous biological network, whereas the type of edge
e = (i, j) ∈ E is denoted as ξ (i, j) = ξ (e), e.g. a co-expression, physical binding,
etc.
A homogeneous graph is simply a special case of a heterogeneous graph where
|TV |= |TE |= 1.
As we briefly mentioned in the previous section additional information about
nodes and edges is often available from the experiments, databases and in a form
of domain expert knowledge (Figure 8). These attributes can be incorporated into
the graph for further analysis. For the convenience let us introduce the notation of
an attributed graph as following:
Let G = (V,E,X ,Y ) be an attributed graph where V is a set of nodes, E is a set
of edges, N and M are the numbers of nodes and edges in the graph. X is an N×D
matrix of node input attributes where each xi is a D-dimensional (row) vector of
attribute values for node vi ∈ V and x j is an N-dimensional vector corresponding
to the jth attribute (column) of X , analogically, Y may represent a M×D matrix
of edge input attributes.
3.3.2. Analysis of heterogeneous graphs
Graph-structured data emerge naturally in many different domains including bi-
ology. Many useful insights about the data can be obtained from using the graph
structural properties as shown in the growing body of research focused on graph
mining [35, 199]. However, in the real world examples graphs can be large, con-
tain many different complex structural patterns, and be noisy, i.e. contain edges
that do not represent real life relations, making effective graph mining to be a
non-trivial task [24].
3.3.2.1. Node Embeddings
Graph algorithms and approaches have become popular both in biology and in so-
cial studies due to the advantages of data representation in a network format [200].
Modern machine learning applications are using network-structured data to iden-
tify patterns and make predictions. To process network data effectively, the first
critical challenge is to find appropriate network data representation and incorpo-
rate graph structure into a feature vector for further application of analysis meth-
ods [201]. These tasks are addressed by a field of representation learning that
aims for automatic feature learning from the given data [32, 202]. Representa-
tion learning allows the replacement of manual feature engineering in machine
learning tasks, e.g. when building classifiers or other predicting models [202].
Depending on the study domain and the machine learning task, such as link
prediction or node classification, various structural graph properties can be incor-
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porated into a machine learning model, e.g. information about local node neigh-
bourhood. The major challenge is to find an effective way to encode these high-
dimensional graph structural properties into a feature vector. Traditional machine
learning approaches in biological and social network analyses have utilized hand-
crafted graph features based on the global and local graph structural properties,
for example, clustering coefficients, node degrees or other carefully engineered
features. However, the downside of such approaches is that hand-crafted features
are not able to adapt during the learning process and creating these features can
be time consuming.
These issues required development of novel network representation methods
that aim to learn low-dimensional vector representations for network nodes, i.e.
embeddings, that encode information about graph structural properties [35, 202].
The objective is to map original node vectors to d-dimensional embeddings so
that similar nodes in the graph are embedded close together (Figure 10). In this
context node similarity is not defined by only topological close location in the
graph, but rather by various node features, i.e. attributes. Once the embeddings
are learned, they can be used in downstream analysis tasks.
Given a graph G = (V,E) with V as the node set and E as the edge set, the
objective of node embedding is to learn a function f : V → Rd such that each
node i ∈ V is mapped to a d-dimensional vector zi where d  |V | and zi ∈ Rd ,
where Rd is a d-dimensional space. The node embedding matrix is denoted as
Z. The learned node embeddings given as output can subsequently be used as
input to mining and machine learning algorithms for a variety of tasks such as
link prediction, node classification [35], community detection, etc.
Figure 10. Low-dimensional vector representations for network nodes.
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3.3.2.2. Graph convolutional networks
In the recent years deep learning methods have gained increasingly critical role
in various domains, being used to learn useful low dimensional representations of
images, text, videos, etc. [203–207]. These methods were inspired by the organi-
zation of the animal brain neural networks. They are built using artificial neurons
(Figure 11 A), i.e. an approximation of a biological neuron, as computational
units [208, 209]. Artificial neural networks consist of stacked layers of intercon-
nected neurons (Figure 11 B), and the depth of the network corresponds to the
number of hidden layers. The network receives a data at the input layer and then
transforms it using non-linear function at each hidden layer. Each neuron at the
hidden layer calculates the weights the input from all the neurons at the previous
layer and sums them and then applies non-linear activation function, e.g. ReLU,
to compute an output [25]. Training procedure starts by setting initial weights to
small random numbers. Learning process involves minimization of a loss func-
tion L(w) that computes the difference between the predicted value or label and
a true label [25, 209]. In order to do that the internal weights of neural networks
should be modified using some optimization technique. It is typically performed
by using gradient descent technique [210]. The loss is backward propagated to
the network resulting in small changes in the weights. The derivative (gradient) of
the loss function dictated the weight update wnew = wold +η∆w. The learning rate
η is introduced as a small constant to ensure the smoothness of weight updates.
Graph neural networks (GNN) are deep learning methods that extend the appli-
cation of existing neural networks to analyze graph-structured data [206,207,211].
Initially proposed by Scarselli et al. [212], a concept of GNN was later developed
into a variety of methods [198, 207]. These methods can be divided into sub-
groups by the type of propagation rule, training method and a type of graphs that
method can be applied to (Figure 12). In the current thesis we will focus on type
of GNNs called graph convolutional networks (GCNs). GCNs is a set of new
deep learning methods inspired by the application of well-established convolu-
tional neural networks (CNNs) [205,213,214]. CNNs allow to reduce the number
of model parameters compare to a fully connected network by applying convo-
lutional operation to a small region of the input at a time and sharing the model
parameters between regions [25, 205, 214]. However, unlike effective applica-
tion to image, text and video types of data, due to complexity of graph-structured
data, i.e. topological structure, lack of spatial locality like in grids, lack of fixed
node ordering or reference point (Figure 13) and often multimodal features, these
methods can not be directly applied on the graph data.
GCNs generalize an operation of convolution from traditional data such as
images or grids to graph data [34, 35, 215, 216]. These methods leverage both
information contained in the nodes and information contained in the relationships
between the nodes. Firstly, we will provide a general description of GCN meth-































Figure 11. Artificial neural networks. A. Schematic representation of the artificial neuron.
The unit receives input xi with associated weight wi from N neurons. The total input to
a unit is the weighted sum over all inputs. B. Schematic drawing of artificial neural
network with four inputs at the input layer and three neurons at the hidden layer. The
loss is computed based on the true and predicted labels and backward propagated to the
network.
central idea of GCN approaches is to learn a function f to generate a node vi rep-
resentation by aggregating its own features Xi and features of neighbouring nodes
X j , where j ∈ N(vi). Borrowing the concept of a convolution filter for image
pixels, the main analogy between CNNs and GCN mechanisms can be explained
as the aggregation of information from the neighbouring pixels or nodes into a
low-dimension representation [198, 207] (Figure 14).
GCN aims to learn a state embedding hv ∈Rd , i.e node representation, that con-
tains neighborhood information for each node. This state embedding hv (equation
3.11) is a d-dimensional vector of node v that can be used to produce an output ov
(equation 3.12), e.g. the node label [207]. In the equation (3.11) f is a parametric
function that updates node state based on the input neighborhood, xv, xed[v], hne[v],
xne[v] are the features of v, features of its edges, states, and features of neighbor-
hood nodes correspondingly. In equation (3.12) g is a local output function that
describes in what form the output is produced [207].
hv = f (xv,xed[v],hne[v],xne[v]) (3.11)
ov = g(hv,xv) (3.12)
In a compact form vectors H, O, XE , X corresponding to all states, outputs,
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Figure 12. An overview of variants of graph neural networks. Image is adapted from
Zhou et al. [207]. Figure demonstrates classification of GNN-based model types. A
branch of methods indicated by the highlighted boxes is considered in the current thesis.
Figure 13. Differences in structure between graph, image and textual data.
edge and node features constructed by stacking can be compactly represented by
equation (3.13) and equation (3.14), where F is a global transition function, and
G is a global output function are stacked versions of f and g for all nodes in a
graph [207].
H = F(H,XE) (3.13)
O = G(H,X) (3.14)
The states are iteratively updated based on the states in the previous layer (see
equation (3.15)).
Hk+1 = F(Hk,X) (3.15)
The computations described by f and g can be interpreted as feed forward neural
networks with learnable parameters. In node classification task GCN (Figure 15)
is trained on the labeled nodes of the graph, effectively propagating the node label
information to unlabelled nodes by updating weight matrices W that are shared
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Figure 14. Low-dimensional representation analogy between images and graphs. In case
of images the features of neighbouring pixels are used to create a representation, in case
of networks - features of the neighbouring nodes.
across the nodes. Learning minimizes a loss function (3.16) [207] where p is the






Similarly to CNNs methods applied for images, video and text, the parameter
learning algorithm in GCNs is based on a gradient-descent [210] and can be gen-
erally described as following [34, 198, 207]:
• Perform forward propagation through the GCN. The states hkv are iteratively
updated.
• Compute the cross entropy loss on known node labels. Backpropagate the
loss. The gradient of weights W is computed from the loss.
• Update weight matrices W at each layer. The weights W are updated ac-
cording to the gradient computed in the last step.
There are two sub-classes of GCNs (12), i.e. spatial and spectral [34,198,207].
Spectral-based approaches adapt graph signal processing methods [217] and de-
fine graph convolutions as application of filters, i.e. convolution operation is in-
terpreted as removing noise from graph signals [198, 207, 215]. Spatial-based
approaches denote graph convolutions as aggregating feature information from
the neighbors. In this work we consider only spatial type of GCNs such as Graph-
SAGE and HinSAGE [35, 218]. GraphSAGE (SAmple and aggreGatE) proposed
by Hamilton et al. [35] is a spatial-based GCN model that addresses several major
issues that other GCN approaches suffer from. The most relevant to this work
is scalability - most of the methods can not be applied to large graphs due to
computational issues, while GraphSAGE is scalable to graphs with billions of
nodes [202,211]. The second issue is the ability to work in an inductive setting as
opposite to the transductive one [34,207,219]. Most of the approaches work with
stationary graphs and are not generalizable in case new node is added to the net-
work. In a nutshell the transductive learning does not generalize to unseen nodes,
while inductive GraphSAGE can generate node embeddings, i.e. node vector rep-




























Figure 15. Schematic depiction of multi-layer GCN for node classification task. Input
graph is characterized by adjacency matrix A and a matrix of node attributes X . The graph
structure is shared over layers, labels are denoted by Yi.
differs GrapgSAGE from other methods is that it generates node embeddings at
each state by sampling and aggregating features from a node local neighborhood.
However, it does not use the full set of neighbors, but a fixed-size set of neighbors
uniformly sampled from the neighbouring nodes at each neighbourhood with the
depth K, e.g. 1-hop, 2-hop, etc (Figure 16). These embeddings can be considered
as a vector containing hash values describing the representation of a node v. This
way in GraphSAGE node local neighbourhood defines a computational graph.
Figure 16. GraphSAGE sample and aggregate approach. Figure is adapted with modifi-
cations from Hamilton et al. [35].
Generally GraphSAGE learning process can be described as following:
• Sample head node local k-hop neighborhood N(v) with fixed sample size.
• Derive node final embedding zv at layer K by aggregating its neighbors
features (equation 3.17).
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• Use node embedding on the final layer to make predictions, compute loss
and backpropagate errors to update weight matrices Wk.
hkN(v)← AGGREGAT Ek(hk−1u ,∀u ∈ N(v))
hkv← σ(Wk ·CONCAT (hk−1v ,hkN(v))
zv← hKv
(3.17)
GrapSAGE proposes three possible aggreator functions, i.e. mean aggrega-
tor, LSTM aggregator and pooling aggregator. Mean aggregator computes an
element-wise mean of vectors hk−1u ,∀u ∈ N(v), LSTM aggregator applied LSTM
method-based [220] to a random permutation of the node’s neighbours, finally
when pooling aggregator is used, neighbors’ vectors are fed through a fully-
connected neural network independently followed by an element-wise max-pooling
operation to aggregate information across the neighbors [35]. The embedding
generation process or forward propagation algorithm using mean aggregator is
formally described by the Algorithm 1. This algorithm assumes that a set of
weight matrices Wk,∀k ∈ 1, ...,K is already learned [35]. At the fist step of the
algorithm the node embeddings are initialized as the input node attributes. i.e.
features, xv (Figure 17). Then at each iteration of the algorithm embeddings of the
node’s neighbours are aggregated.
After feature vectors of the neighbouring nodes are aggregated, GraphSAGE
concatenates the node current representation, hk−1v , with the aggregated neigh-
borhood vector, hkN(v) (Algorithm 1, Figure 17). This concatenated vector is fed
through a fully connected layer with nonlinear activation function σ , which trans-
forms the representations for the next step of the algorithm hkv, ∀v ∈ V . On the
next iterations the model adds information from the further neighbourhoods to
the embeddings. However, the dimensionality of the embeddings remains con-
strained, i.e. mapping function compresses the neighbourhood information into
the low dimensional vector. Through the incorporation of node features to the
model, GraphSAGE also learns the topological structure of each node neighbor-
hood as well as the distribution of node features in the neighborhood. The main
advantage of the GraphSAGE algorithm is that the trainable parameters are shared
across the nodes, i.e. the same aggregation functions and weight matrices Wk are
used for the generation of the embeddings for all nodes. During this process only
node neighbourhood structure and node input attributes are changing. This way
GraphSAGE provides regularization and allows to generate embeddings for the
nodes that have not been seen during the training [35]. The details of Graph-
SAGE loss computation and application of the model to node classification task
are described in Section 3.3.2.4.
GraphSAGE uses a uniform sampling function and samples neighbourhood
nodes with replacement in case the sample size is larger than a node degree. The
size of a sample at each layer is defined by the user. Different uniform samples






















































Figure 17. Information propagation in GraphSAGE algorithm from the local node neigh-
bourhood (figure is adapted with modifications from Hamilton et al. [202]). A Illustration
of the input graph. An example demonstrates computation of embedding for a node A.
B Embedding for a node A is generated using neighbouring nodes’ embeddings from 2-
hop neighbourhood (K=2 in Algorithm 1). Grey boxes represent aggregation functions γ ,
weight matrices Wk and fully connected layer with nonlinear activation function σ .
pected runtime of a single batch is unpredictable and in the worst case O(|V |).
In contrast, the per-batch space and time complexity for GraphSAGE is fixed at
O(∏Ki=1 Si), where Si, i ∈ 1, ...,K and K are user-defined constants representing
sample sizes at each layer [35, 198, 207].
GraphSAGE is developed for homogeneous feature-rich graphs, for example,
biological graphs with a number of node attributes representing gene meta data
(see Figure 8a). However, real life examples often imply working with heteroge-
neous graphs, that, for example, can contain nodes and edges of multiple types
(Section 3.3.1). In the next Section 3.3.2.3 we will introduce extension of Graph-
SAGE model to heterogeneous graphs.
3.3.2.3. GCN extension for heterogeneous graphs
A HinSAGE [218] is an algorithm from the family of spatial GCNs - a generalisa-
tion of the GraphSAGE algorithm [35] for heterogeneous networks. HinSAGE is
designed for the heterogeneous networks that can contain multiple types of edges
and nodes, however, in this work we restrict the description only for the network
with multiple edge types. For example, in the context of biological networks dif-
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Algorithm 1: GraphSAGE embedding generation algorithm [35] (forward
propagation) with Mean Aggregator.
Input: Graph G(V,E); input features {xv,∀v ∈V}; depth K, weight
matrices Wk, ∀k ∈ {1, . . . ,K}; non-linearity σ ; neighborhood
function N : v→ 2V
Output: Embeddings zv for all v ∈V
1 h0v = xv,∀v ∈V ;
2 for k = 1 . . .K do





5 hkv← σ(CONCAT(Wkhk−1v ,WkhkN(v)))
6 end
7 hkv← hkv/‖hkv‖2,∀v ∈V ;
8 end
9 zv← hKv ,∀v ∈V
ferent edge types can represent biological relations, i.e co-expression, physical
interactions between the proteins. The main difference from the homogeneous
GraphSAGE [35] is that HinSAGE takes into account individual edge types t ∈ T ,
where T is a set of all edge types in the given graph (Figure 18).
Recall that GraphSAGE forward propagates node information across the graph
to compute node embeddings (see Algorithm 1). The intuition behind is that at
each iteration the search depth for a node increases, aggregating information from
further neighborhood of the node. HinSAGE operates in a similar manner, but
models each edge type t separately (see Algorithm 2). It models the representa-
tion of the sampled neighbouring nodes at each layer for each edge type and com-
bines it with the nodes representation from the previous layer. This concatenated
vector is fed through a fully connected layer with nonlinear activation function σ
similarly to GraphSAGE. In the Algorithm 2 Nt(v) is a neighbourhood of node v
connected by edges of type t, W k and W kt,neigh are trainable weight matrices, where
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Figure 18. Generation of node embeddings in heterogeneous graph. HinSAGE algorithm
generates node embeddings for each sub-graph, consisting of the same type of edges, and
concatenates them similarly to GraphSAGE algorithm. Figure demonstrates an example
of biological heterogeneous graph where nodes represent genes, and edges of different
colors depict biological relationships, such as co-expression, PPI and epistatic interac-
tions. Neighbourhood states of co-expression, ppi and epistasis sub-graphs are aggregated
by function γ . The aggregated state of the neighbourhood hkNA is then concatenated with
node A representation on the previous (k-1) layer and fed through fully connected layer
nonlinear activation function σ .
Algorithm 2: HinSAGE embedding generation algorithm [218].
Input: Graph G(V,E,T ); edge type mapping ξ : E→ T , input features
{xv,∀v ∈V}; depth K, weight matrices Wk, Wkt,neigh ∀k ∈ {1, . . . ,K}
and ∀t ∈ T ; non-linearity σ ; neighborhood function for the
relationship t: Nt : v→ 2V
Output: Embeddings zv for all v ∈V
1 h0v = xv,∀v ∈V ;
2 for k = 1 . . .K do
3 for v ∈V do













9 hv← hkv/‖hkv‖2,∀v ∈V ;
10 end
11 zv← hKv ,∀v ∈V
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3.3.2.4. Node classification
Recent advances in network analysis demonstrate that methods based on GCNs
outperform other traditional methods for many classification tasks on network
data [34, 35]. For node classification task, such as node classification of genes
into disease/non-disease classes, the major idea of the method is to train a model
on a small subset of nodes, and then apply a classifier to the nodes with unknown
labels [202]. The classification is performed by comparing node embeddings and
computing a loss between the true-labeled and predicted output. GraphSAGE
and HinSAGE use affinity scores to calculate loss. The affinity score between
two given nodes can be defined as A(zu,zv) = zTu zv. This is the cosine similarity
between the two embeddings zu and zv [204]. The learning task is to maximize the
score between nodes similar nodes, and minimize the score of the less similar pairs
in the embedded space. Cross-entropy loss can be used to estimate performance
of classification where the output is a probability value between 0 and 1. Binary
cross-entropy loss for a node can be computed as following [35, 204]:
L(zu) =−log(σ(zTu zv))−Qlog(σ(−zTu zvn)) (3.18)
In equation (3.18) where Q is an optional weight that defines the number of neg-
ative samples. This loss function implies that closer nodes would have similar
embeddings, while nodes located further from each other in the projected space.
Alternatively, the equation for loss function can be written in a more conventional
way using label binary classification label, yi ∈ Z, associated with each node. To
learn to map nodes to their labels, embedding vectors, zi, are fed through a lo-
gistic, or sigmoid, function ŷi = σ(zTi θ), where θ is a trainable parameter vector.
The cross-entropy loss increases as the predicted probability diverges from the
true label. Expression (3.18) can be rewritten as following :
L = ∑vi∈V yilog(ŷi)+(1− yi)log(1− ŷi)) (3.19)
During the model training the gradient computed according to this equations
(3.18) and ( 3.19) can be back-propagated to optimize model parameters Wk using
stochastic gradient descent [35, 202, 210].
3.3.3. Summary
In this Chapter we have described a the transformation-based biological data
integration approach and state-of-the-art deep learning algorithms for network-
structured data. We have introduced a concept of representation learning in the
context of graph-related machine learning tasks. We have also demonstrated how
GCN approach can be extended to heterogeneous graphs and how it can be applied
for node classification task.
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4. INTEGRATING HETEROGENEOUS DATA SETS
RELATED TO ALZHEIMER’S DISEASE
(PUBLICATION I)
One of the emerging needs and associated challenges in the biological sciences
at the present moment is methods for effective combination of the heterogeneous
data sets, such as transcriptomics, proteomics or GWAS, describing the biological
process or a disease at the individual levels [12, 15, 221, 222]. The integrated reli-
able data sources could be further explored by the scientific community and anal-
ysed together with other complimentary data sets. Well-designed and thoroughly
described integrated data sets can be repurposed for a variety of applications, e.g.
to generate or test novel hypotheses, to increase the reproducibility of research
and provide general advancement in clinical and biological understanding of the
disease through the analysis [223].
In this chapter we will describe the data integration approach developed for
the combination of the heterogeneous data sets related to Alzheimer’s disease.
We will also demonstrate how transformation-based integration uncovers disease
mechanisms that would not be detected otherwise. This approach can be applied
in the integration tasks related to other diseases and biological processes.
4.1. Bringing together disparate data sets related to
Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative disorder that progresses with age
and is accompanied by a severe loss of memory and other cognitive abilities. Cur-
rently there are no effective treatments that are able to stop the disease completely.
Furthermore, the development of the effective treatments is delayed because of an
insufficient understanding of the disease at the systemic level in human.
Various experiments have been performed to capture the underlying disease
mechanisms and identify disease biomarkers and potential new drug targets [111,
224–227]. Such experiments are carried out by the scientists working in different
domains, e.g. proteomics, genomics, clinical diagnostics, etc. The results of such
studies are deposited in the databases designed for collecting the data of simi-
lar types, e.g. IntAct [3, 4], ArrayExpress [1, 2], ADNI [5]. However, in order
to obtain a comprehensive systematic view on the disease from these individual
complementary data sets we need to integrate them in an effective way (Figure
19).
This task was addressed by AgedBrainSYSBIO1 consortium. We formulated
the aim of our study as following:
1AgedBrainSYSBIO - is a four year collaborative research project funded by the European
Commission under the Health Cooperation Programme of the 7th Framework Programme (FP7);
Grant Agreement No 305299; http://www.agedbrainsysbio.eu/
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• To create a collection of reliable data sets of various experimental and com-
putational origins, including both publicly available and newly generated
disease-specific data sets.
• To develop an integrative approach for combining these data sets in a con-
sistent manner.
• Investigate if application of the state-of-the-art machine learning methods
on the integrated data will identify disease related mechanisms that would
not be discovered otherwise.
PPIs










Figure 19. Data integration in Alzheimer’s disease. Diagram represents the enrichment
of knowledge about Alzheimer’s disease by combing genomics, proteomics and clinical
phenotype data.
4.2. Collecting and generating data sets related to Alzheimer’s
disease
The success of the data driven research relies highly on the quality and richness
of data collections that researchers are working with. In the study of Alzheimer’s
disease we have applied systems biology approach to observe, combine and un-
derstand disease mechanism on various molecular levels. We have generated and
collected 64 data sets of 6 data types originating from 9 data sources. Data sets
included experimental and computational origins. Collection contains such data
types as protein-protein interactions, gene co-expression in disease and healthy
samples, gene co-expression in disease-related brain regions, epistasis, genome-
wide association studies, gene expression in the whole brain regions, and positive
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Darwinian selection data. For the reader’s convenience the detailed description of
each data type is provided in Section 2.2.
These data sets come from publicly available repositories as well as are gen-
erated by consortium members. For the combination of individual homogeneous
co-expression data sets at the stage of data generation we performed multi-staged
integration, when individual data sets were analysed and then the joint conclusion
was drawn by the integration of the individual results. For example, we have com-
puted co-expression in AD and healthy samples in microarray data sets coming
from different individual experiments. In order to combine results of individual
analyses, we have applied RRA method [120] (see Chapter 3 for details) to find
genes with similar expression patterns over all individual experiments. Integration
of such data can reveal functional relations between the genes.
To ensure the quality of the data collection we performed rigorous filtering and
quality control of the combined data sets. Every interaction in the individual data
sets contains a value (score) stating its importance. For example, the p-value in
GWAS and epistatic data sets or MI score [228] for the PPI data sets from IntAct
database [3,4]. We filtered the data sets using an appropriate threshold for each of
the score type to ensure that only reliable interactions from each of the data sets
could be integrated, i.e. we only kept the data record with p-value ≤ 0.05 and MI
score ≥ 0.45.
The selected data are heterogeneous in their nature which makes it difficult
to understand the relationships between the individual data types as well as rela-
tionship with clinical phenotype, i.e. AD. To obtain a comprehensive picture of
the interactions within Alzheimer’s disease we have applied transformation-based
data integration approach [15].
4.3. Transformation-based data integration
Transformation-based data integration approach implies the combination of data
sets of multiple data types after transforming each of them into an intermediate
form, such as a graph [15]. This approach can be used to integrate many types of
data as long as the data contain a common unifying feature.
Collected data sets can be divided into two groups - data sets describing bio-
logical relation, i.e. co-expression, PPI, epistasis, and data sets containing specific
information about genes or SNPs association with the disease, i.e. GWAS or pos-
itive selection data sets.
In our work we represent each individual interactions data set as a graph (Fig-
ure 20), where nodes stand for proteins, genes, SNPs etc., and where edges il-
lustrate the relationships between the entities e.g. protein-protein interaction,
co-expression, epistatic interaction. Multiple individual graphs are then com-
bined into one graph constituting HEterogeneous Network-based data set related
to Alzheimer’d disease (HENA).
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Figure 20. Transformation-based data integration pipeline. Preprocessed data sets con-
tain information about the interactions between genes, proteins, SNPs, and information
characterizing them, e.g. node attributes. Interaction data sets contain PPI, co-expression
and epistatic interactions and inter-genic regions interactions (IGRI) as its sub-type. Node
attributes originate from GWAS, positive selection and gene expression in brain regions
from Allen Brain Atlas. Integration is performed using transformation-based approach.
Data sets from the interaction group are converted into intermediate graphs, where nodes
are genes, proteins, SNPs and the edges are the relations such as PPI (violet), epistatic
interaction (green) or co-expression (red). All individual node identifiers are mapped to
gene level and converted to ENSEMBL name space. Individual graphs are then combined
into one heterogeneous graph with possible multiple edges between 2 nodes. Addition-
ally, each node is characterized by a set of attributes such as ENSG ID, corresponding
gene name, gene biotype, SNP ID, GWAS p-value, positive selection p-value and aggre-
gated expression in 231 brain regions.
or proteins, can be mapped. We map identifiers from each individual data set
to a common Ensembl database name space (please see Section 2.2 for details).
The identifiers provided by Ensembl database (ENSG ID) are selected to ensure
mapping of the multiple alternative gene and protein names to the unique identi-
fier. We then combine individual graphs into a single heterogeneous graph with
multiple edge types (please refer Section 3.3.1 for more information about the
heterogeneous graphs). The combined data are represented as a single undirected
graph where each interaction between a pair of nodes is described by a set of
attributes outlined in Table 4.1.
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Edge attribute Description
ENSG.A ENSG ID of the node A
ENSG.B ENSG ID of the node B
Score Value, associated with the interaction.
It represents the importance of an interaction,
i.e. strength, significance.
Interaction type Type of biological relation between node A and B,
i.e co-expression, PPI, epistasis.
Data source ID
in HENA
Short name of the data source of the interaction.
In case multiple data sets originate from one data source,
data source name is appended by individual data set.
Table 4.1. List of edge attributes in HENA data set.
However, it is not always possible to map a SNP directly to the location of
a gene, instead it can mapped to the intergenic region (IGR). In this case IGR
is uniquely identified by two flanking genes. We refer epistatic interactions that
contain IGR as intergenic region interactions (IGRI).
Combined disease related information about each node (gene), i.e. GWAS as-
sociation, positive selection, expression in the brain regions, is described as node
attributes shown in Table 4.2. Node attributes (or features) were collected for the
genes present in the heterogeneous graph. Some sets of features are incomplete
due to the absence of the required information in the various sources describing
the genes. For each node a list of attributes is a vector of length 237.
Node attribute Description
ENSG ENSG ID of the node
Gene name Alternative human readable gene name.
Biotype Gene biotype according to Ensembl classification
i.e. protein coding, long non-coding, etc.
SNP ID SNP identifier from GWAS data set.
GWAS p-value P-values corresponding to SNPs from GWAS data set.
PS p-value P-value of gene association
with positive Darwinian selection.
Brain region ID #1 Aggregated gene expression of the node in
brain region ID #1
... ...
Brain region ID #231 Aggregated gene expression of the node in
brain region ID #231
Table 4.2. List of node attributes in HENA data set.
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4.4. Learning from the integrated data
To study if novel information about the disease can be inferred from HENA, we
attempted to identify genes that were associated with Alzheimer’s disease us-
ing information about genes and interactions of different types between pairs of
genes. We also aimed to understand if network representation of heterogeneous
data would be useful in this task. The study workflow is depicted on the Figure
21.
Figure 21. Identification of genes potentially associated with Alzheimer’s disease in
HENA data set. The diagram represents individual steps of the analysis for the identifica-
tion of disease related genes.
The most straightforward way to identify genes that are associated with Alzheimer’s
disease would be to use a supervised machine learning method, where genes are
labeled based on the association with Alzheimer’s disease. Using the labeled set
of genes we can train a model to find a decision boundary between two classes,
and apply it to predict the association for the rest of the genes.
The problem is that such a set of confirmed positive and negative associa-
tions of genes and Alzheimer’s disease is not yet well defined. Due to the limited
technological advances the current research of Alzheimer’s disease is not able to
provide sufficient data to define the difference between patients and healthy indi-
viduals at the level of molecular interactions. One example to illustrate this issue
is an inability to measure the presence or absence of the interaction between the
proteins in a live brain regions.
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4.4.1. Defining a node class
The genes, and proteins as their products, can be defined as associated with the
disease based on genome-wide association studies and based on curated knowl-
edge. Despite the substantial number of studies that has been carried out in
the field of Alzheimer’s disease, there is no clear agreement between the stud-
ies on the set of genes that are clearly associated with the Alzheimer’s disease
[111,229,230]. It is even more challenging to define the genes that are not related
to the disease, which leads to inability to define the negative class, i.e. genes that
are clearly not associated with the Alzheimer’s disease. As the results of HENA
study demonstrate, the noisiness of the gene labelling poses a serious challenge.
Therefore, we adopt the following strategy:
• We create three classes of genes: positive, negative and unknown. We use
information about the nodes from HENA to assemble a set of genes associ-
ated with the disease based on GWAS data set and Alzheimer’s related PPI
data set collected in HENA. Negative gene label corresponds to the genes
that are defined as essential non-disease genes in the evolutionary study by
Spataro et al. [231]. The rest of the genes are labeled as unknown.
• Next, we explore one-class or anomaly detection problem in order to assess
the quality of class separation.
• We use different feature sets, i.e. biological features and graph structural
features, and apply two supervised approaches to classify the nodes with
the unknown association with the disease.
• We apply supervised models, i.e. Random Forest and HinSAGE method,
on set of genes labelled as unknown and suggest most likely candidates for
Alzheimer’s associated genes. Additionally, we perform qualitative analy-
sis by exploring the existing body of research about the suggested genes.
4.4.2. Full graph exploration
Due to the fact that we are focusing on genes and their relation to the disease,
we have excluded IGRs and corresponding IGRIs from this analysis. We also
kept only strong co-expression interaction in disease-associated brain regions with
Spearman correlation coefficient ≥ 0.5. The summary of the resulted graph is
shown in Table 4.3.
# nodes # edges
full graph 24825 9740721
PPI subgraph 10445 52003
co-expression subgraph 14634 9671535
epistasis subgraph 13881 17183
Table 4.3. Number of nodes and edges for each sub-graph in HENA data set.
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In Figure 22 we can see the whole picture. The graph consists of one largest
component in the center, and many small components populating the "ring" clos-
est to the central connected component. Alzheimer’s genes, which are the minor-
ity, are shown with larger size red-colored nodes. They are seemingly uniformly
distributed in the connected component as well as in the rings, which demon-
strates that the problem of gene classification according to their association with
the disease is not trivial.
Figure 22. Visualization of HENA data set using Gephi platform [232]. Colors represent
node types: red corresponds to the association with Alzheimer’s disease, yellow node
color indicates the genes that have no direct association with the disease, purple colored
are genes with no information about their association with the disease.
4.4.3. Community detection analysis
In order to explore the connectivity of the nodes and identify potentially func-
tionally related groups of nodes we performed clustering of the whole graph.
We applied infomap clustering method [233, 234] to identify structurally related
groups of nodes. By observing the resulted infomap communities we noted that
Alzheimer’s genes are often connected via one hop or two hops.
The analysis of communities also suggests that there are several big clusters
that mostly have internal connections of one particular type, for example, a com-
munity of genes with PPI connections, or a separate cluster of co-expressions.
This observations does not contradict the previous knowledge about biological
networks properties of being modular, small-world networks. In the biological
terms it means that nodes sharing biological functionality are located within close
proximity in the network [235, 236]. Taking into account that clustering method
disregards the heterogeneity of the edges, we formed a hypothesis that the way
the genes are connected reflects the type of the interaction they are involved in.
Based on the results of community detection analysis we collected additional
node features that rely on graph structure.
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4.5. Feature generation
To understand if network topological features can provide additional information
for the model, we have created three sets of features that describe biological in-
formation, graph structural information and a combination of both.
4.5.1. Graph features
The results of community detection lead us to believe that we need to introduce
gene features that exploit the graph-related information as it can improve the clas-
sification results. We collect the following features for each gene:
• an absolute number and a fraction of genes associated with Alzheimer’s
disease in a one-hop neighborhood via each edge type,
• same features for two-hop neighborhood,
• 256-dimensional node embeddings obtained by applying unsupervised Graph-
SAGE [35] (Section 3.3.2.2) on subgraphs consisting of one edge type, i.e.
PPI, co-expression and epistasis. The resulting embeddings are concate-
nated, consisting in total of 768 features.
4.5.2. GraphSAGE embeddings
Recent advances in network analysis demonstrate that methods based on graph
convolutional networks (GCN) outperform other traditional methods for many
classification tasks on network data [34]. GraphSAGE model, proposed by Hamil-
ton et al. [35], can generate node embeddings – node vector representations – for
nodes that were not seen during the training (Section 3.3.2.1).
In this study we use unsupervised version of GraphSAGE, where for each node
we learn embeddings based on both node features and the graph structure. Each
node is then represented via a numeric vector of a specified fixed dimension (256
in our case) that captures the node properties in the graph in addition to the node
features. Moreover, as we deal with a heterogeneous graph, we learn embeddings
for each of the three subgraphs, where a subgraph consists of edges of a particular
type. Therefore, the dimensionality of the resulting embedding vector for each
node is 256× 3 as we concatenate embeddings from subgraphs for each edge
type.
4.5.3. Feature sets
To summarize, we represent each node via one of the following sets of node fea-
tures: 1) Biological features here represent levels of aggregated gene expression
in 231 brain regions and a value, representing genes, expressed higher in dis-
ease associated regions (CA1-CA4, DG, SptN, subiculum) compared with the
rest of the brain regions. This value was obtained by the application of Wilcoxon
test [20]. For further analysis we disregard genes that do not have the biological
information about the expression in 231 brain regions for a fair comparison with
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the graph-related set of features. The statistics of class distribution in the reduced
data set is demonstrated in Table 4.4. 2) graph-related features that consist of a
set of graph embeddings learned via unsupervised GraphSAGE and neihborhood
related features discussed in the beginning of Section 4.5.1. Finally, 3) a union of
both sets of features, which we refer to as all features.
disease non-disease unknown total
initial 1018 1430 22377 24825
reduced 854 1421 15286 17561
Table 4.4. Class distribution in the initial and reduced datasets.
In the following Section 4.5.4 we investigate these node features to select the
most useful features for the task of gene classification according to their associa-
tion with Alzheimer’s disease.
4.5.4. Exploration of feature sets
As we mentioned earlier, positive and negative classes of genes are very noisy.
Therefore, we adopt anomaly detection techniques. The common anomaly de-
tection approach is to find the lower dimensional embeddings of the original data
where anomalies are expected to be separated from the regular data. The lower di-
mensional embeddings are then reconstructed, which means that they are brought
back to the original data space. Reconstruction of the data with the low dimension
embeddings is expected to represent the underlying generative model of the data.
The reconstruction error of a data point is defined as the error between the original
data point and its low dimensional reconstruction. For the anomaly detection we
adopt a particular type of neural networks called autoencoder [237]. An autoen-
coder learns a dense representation of the data by reconstructing it, where the goal
of the learning is to minimise the difference between the data provided as an input
and the reconstructed data. A typical architecture of an autoencoder resembles
an hourglass, with the sizes of input and output layers (at the edges) equal to the
dimensionality of the data feature vectors, and layers of lower dimensionality in
between. We train three autoencoder models – using sets of biological, graph-
related, and all the features (refer to Section 4.5.3 for the details). Each of the
models is trained on a subset of negatively labeled genes and applied to the rest
of the data points. We measure the mean reconstruction error of data points for
each of the gene classes. We expect to see a larger difference in the reconstruction
error of the positively labeled gene set.
The difference between the errors of different classes is quite small. The ideal
scenario for the density plots is when the reconstruction error distribution for the
negative genes does not overlap with the density distribution of the positive class.
Figure 23 demonstrates the separation of three classes using three feature sets.
From the density plots we can observe poor separation in general, however, we can
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Figure 23. Reconstruction mean squared error (MSE) distribution density using three
sets of features.
notice that graph-related and combined feature sets seems to be more informative
for the classification task than the biological feature set.
4.6. Supervised and semi-supervised approaches
Next, we adopt a classical supervised strategy, where a Random Forest classifier
is trained on the set of positive and negative genes for each of the feature sets
(for the description of the feature sets see Section 4.5.3). The results are shown
in Table 4.5. We then apply the model to a set of unknown cases and rank them
according to the probability score. The higher the probability, the more likely the
gene is associated with the Alzheimer’s disease.
We also apply an algorithm from the family of Graph Convolutional Networks
- a generalisation of the GraphSAGE [35] to heterogeneous networks- a Hin-
SAGE [218] algorithm.
The HinSAGE model (see Algorithm 2) is a semi-supervised approach, where
it is trained using labeled head nodes, i.e. genes of positive and negative classes,
while the whole network structure is used for the feature vector aggregation (in-
cluding connections to genes with unknown class as well as their features).
As in the case of random forest classifier, we rank the predictions of HinSAGE
model for the unlabeled genes. The results of both models’ performances are
shown in Table 4.5.
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HinSAGE
Precision Recall F1 score ROC AUC
all 0.40 0.98 0.57 0.60
graph 0.40 0.98 0.57 0.66
biological 0.37 0.94 0.54 0.56
Random Forest
all 0.50 0.50 0.50 0.82
graph 0.50 0.50 0.50 0.83
biological 0.43 0.27 0.33 0.56
Table 4.5. Comparison of HinSAGE and Random Forest classification model perfor-
mance using different feature sets.
We have compared the results of random forest and HinSAGE model per-
formance for biological, graph-related, and joined set of features. The results
demonstrate that the performance of both models improves with the use of graph
features. Both models showed the worse performance on a set of biological fea-
tures. However, HinSAGE on biological features uses the initially provided non-
graph features, and propagates this information exploiting the graph structure. It
demonstrates better performance than Random Forest on a set of biological fea-
tures. Random Forest on graph-related feature set slightly improves the perfor-
mance, and HinSAGE on graph features is the best performing method taking to
account F1 score, i.e. a harmonic average of the precision and recall. However,
we can observe that the HinSAGE recall is substantially higher than Random For-
est and the precision is slightly decreased. This can be influenced by a number of
data properties and model parameters that require optimization. For example, cur-
rent study implied building classification models for imbalanced data with noisy
labels, meaning that there is no biological ground truth in case of defining a nega-
tive class based on the assumption that genes are not related to the disease. Model
own parameters, i.e. a number of sampled nodes at each neighbourhood, selected
prediction threshold, distribution of positive and negative class in the whole pop-
ulation of genes to estimate weights for positive and negative class in cross binary
loss function, etc., require more experiments to explore model best setup. In the
frames of the current work we aimed at exploring whether graph-related data fea-
tures provide information useful for the classification and have observed improve-
ments in metrics for both classification models. Undoubtedly, more investigation
and careful data class definition is required which is a case for the future work.
Graph structure helps to capture complex relationships
To explore the classification results of the algorithms we performed qualitative
analysis by checking the existing body of research. For this purpose we have
explored additional independent resources to assess the result in a disease con-
text. We have created a list of genes, shown to have a strong association with the
disease, from the following resources:
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• GWAS [238–240] and genome-wide association study by proxy (GWAX)
study [241].
• list of Alzheimer’s disease-specific autoantibodies in human sera [229]
• list of genes reported to be associated in Alzheimer’s disease downloaded
from MalaCards database [230]
• results of integrative transcriptome analysis [242]
The individual gene lists were extracted and combined. These external gene
lists were assembled independently from HENA data set and were not used in the
training and testing procedure to calculate the performance metrics, i.e. ROC and
F1 measures, of random forest and HinSAGE models. Recall that we have classi-
fied 15286 genes labeled unknown. The genes present in these external gene lists
were then searched among the predictions of the random forest and HinSAGE.
Classification results, i.e. result for genes with unknown class, contained 169
genes that were present in the assembled list of 373 genes. Additionally, we have
compared external gene lists with the genes labeled as disease-related and non-
disease in classification task resulting correspondingly in overlaps of 88 genes and
34 genes. The latter again points to the difficulty of defining positive and negative
class due to the lacking biological ground truth precisely determining the class
separation.
For each model results, we have counted genes with the assigned probability
≥ 0.5 to be associated with Alzheimer’s disease. Out of these 169 genes, ran-
dom forest classified 14 genes to be associated with the disease while according
to the probabilities assigned by HinSAGE, 154 genes were associated with the
disease. Taking into account that GWAS studies are often used for thorough bi-
ological investigations and generation of novel hypotheses, we have focused on
thee novel GWAS genes (ACE, ADAMTS4 and CLNK) recently reported in three
independent GWAS meta analysis publications [238–240]. We have observed
that HinSAGE classified these genes as related to Alzheimer’s disease with the
probabilities 0.81, 0.93 and 0.88, while random forest did not classify them as
Alzheimer’s disease related genes.
These qualitative findings of the subset of genes demonstrate that graph struc-
ture is a rich data source that helps to capture complex relationships and find the
distinctive patterns that are not easily detectable otherwise.
4.7. Summary and impact
In our work we have combined the heterogeneous experimental data from various
sources into one network-structured data set HENA. Combining HENA with the
external complimentary data sets provides the possibility of discovering genes
potentially involved in disease mechanisms.
Prediction of genes related to complex diseases, such as Alzheimer’s disease, is
not a trivial task. The ambiguity in the definition of the node class, i.e. relation to
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the disease, and selection of the informative features strongly influences the model
performance. However, we have demonstrated the advantage of state-of-the-art
GCN-based methods over classical supervised approach for the classification of
genes related to Alzheimer’s disease. We have also demonstrated the advantage
of using network structural information in node classification task compared to
using biologically determined features alone.
4.8. Contribution
In this project my contributions were: collection, preprocessing and analyzing
microarray data sets related to Alzheimer’s disease (co-expression data sets in
Alzheimer’s disease and normal samples and co-expression in brain disease-associated
regions were created), filtering of PPI data from IntAct, aggregation of gene ex-
pression from Allen brain atlas; developing a transformation-based integration for
heterogeneous data sets; creating HENA data set; application of GCNs for gene
classification; manuscript writing, preparation of figures.
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5. STUDYING DISEASE PATHOGENESIS USING
DATA INTEGRATION APPROACH (PUBLICATION II)
Disease pathogenesis is a complex biological process that can be investigated on
different experimental levels including transcriptomics or proteomics studies, in-
vestigation of the specific clinical patients phenotypes, etc.
In this chapter we demonstrate how the application of data integration ap-
proaches for combining the results of these individual studies and experimental
analysis allows to find hidden relationships between the data and the phenotype
of interest and obtain the coherent view on the disease pathogenesis.
For the reader’s convenience the individual data types and statistical methods
mentioned in this chapter are described in the Chapters 2-3.
5.1. Studying the pathogenesis of psoriasis
Psoriasis is a chronic complex inflammatory disease that affects skin and is as-
sociated with systemic inflammation and many serious comorbidities such as
metabolic syndrome or cancer [243, 244]. Important discoveries about psoria-
sis pathogenesis have enabled the development of effective biological treatments
by targeting the members of T helper 17 pathway [245–248]. However, it has
not been settled whether psoriasis is a T cell-mediated autoimmune disease, i.e.
caused by the response of autoantigen-specific T cells, or rather autoinflammatory
disease due to excessive stimulation of innate immune receptors [249–252].
Although autoimmunity and autoinflammation both lead to self-directed in-
flammation, their mechanisms of action differ. Autoimmunity involves adaptive
immune cells targeting various autoantigens, while autoinflammation involves in-
nate immune mechanisms without specific autoantigen involvement [253].
Given this problem, we applied multi-staged data integration framework to
study this complex biological process on different levels ranging from transcrip-
tomics to specific patient phenotypes (Figure 24). We analysed various types of
experimental data, i.e. gene expression, protein concentration in plasma, and clin-
ical meta-data about the patients at the individual levels exploring each data type
association with the disease pathogenesis. Subsequently, we brought together the
results of individual analysis using available domain knowledge to form a more
systematic view on the disease.
We formulated the aims of our study as following:
• To find evidence confirming either autoimmune or autoinflammatory hy-
potheses of psoriasis pathogenesis.
• To understand the connection between specific phenotypes of psoriasis pa-
tients and signs of systemic inflammation.
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Figure 24. Integrative data analysis in psoriasis pathogenesis study. Individual data types
were analysed separately using appropriate statistical methods implemented in R language
[254]. The analysis results were combined and interpreted using domain knowledge.
5.2. Gene expression and cell fluorescent microscopy reveal
the signs of innate immunity in psoriasis
We measured gene expression in psoriasis patients in disease-affected lesional and
seemingly healthy non-lesional skin biopsy using qRT-PCR, and compared it to
the expression in healthy individuals.
Principal component analysis (Section 3.2.1) of the gene expression data was
able to separate the lesional skin samples from the other studied groups. At the
same time psoriatic non-lesional skin samples mostly overlapped with control
group. Although PCA did not distinguish healthy skin from psoriatic non-lesional
skin, we were able to detect significant differences at the level of individual genes.
Our comparative gene expression and hierarchical cluster analysis revealed
important gene circuits involving innate receptors. We used differential gene ex-
pression analysis to find the genes that could demonstrate the difference between
these three conditions.
In our study we confirmed that gene expression of known psoriasis related
Th17 pathway members and other pro-inflammatory cytokines associated with
psoriasis pathogenesis (Figure 25) were significantly increased in psoriatic le-
sional skin in comparison to non-lesional and control skin. We also showed
that several immunoregulatory genes and marker transcription factors were up-
regulated in psoriatic skin. Additionally, hierarchical cluster analysis followed by
multiscale bootstrap resampling [170] helped to find the groups of genes involved
in biological processes and describe their roles in disease pathogenesis. For ex-
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Figure 25. Key cells and mediators in the transition from innate to adaptive immunity in
psoriasis. Pathway structure is adapted from Nestle et al. [253]
Our study is the first to describe increased expression of EOMES gene in pso-
riatic lesions and in non-lesional skin at mRNA as well as protein level. The
product of this gene is an important transcription factor for the development of
virtual memory CD8+ T cells. These cells have innate-like functions, such as
the capability to rapidly produce inflammatory cytokines in the absence of anti-
genic recognition [256–258]. Immunofluorescent microscopy of psoriatic skin
confirmed that a fraction of T cells indeed contained EOMES protein in their nu-
clei.
As autoinflammatory diseases are often associated with inflammation activated
in response to stress signals, we studied the gene expression of the corresponding
genes, e.g. innate receptors and inflammasome components. Our results con-
firmed recently discovered possibility of several innate receptors being involved
in the pathogenesis of disease [259] (Figure 26a).
Another important regulator of innate immunity is caspase-1 enzyme encoded
by CASP1 gene [260]. We used fluorescent microscopy together with staining to
investigate its activation in the skin biopsies. We measured and compared fluores-
cent intensities in healthy control, lesional and non-lesional skin (Figure 26b-e).
We applied Kruskall-Wallis test [261], followed by post-hoc Dunn’s test [262]
to determine which groups were significantly different. We didn’t detect statis-
tically significant differences between non-lesional and healthy skin. However,
the fluorescence intensity was significantly higher in psoriatic lesion in compar-
ison to healthy skin or non-lesional skin of psoriasis patients indicating CASP1
activation in lesional skin (Figure 26f). At the same time we were not able to iden-
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Figure 26. Innate receptors’ up-regulation and inflammasome activation in psoriatic le-
sions (figure is adapted from Šahmatova & Sügis et al. [255]). (a) mRNA expression of
genes encoding innate receptors relative to gene expression of ACTB in skin biopsy sam-
ples obtained from lesional (L) and non-lesional (NL) skin of psoriasis patients and from
age-matched control individuals (C). Stars above the groups C and NL depict their sig-
nificance level from L samples. **P < 0.001, *P < 0.05. (b–e) Fluorescence microscopic
images illustrate caspase-1 activation in control skin (b) psoriatic non-lesional skin (c)
or psoriatic lesional skin (d) biopsy frozen sections. (e) Represent control slides. White
bars in 20x images represent 75 µm. White dotted lines indicate the basal membrane. (f)
Green fluorescence intensity was measured from the slides in fixed skin areas (from slides
of two different individuals and 2–3 different areas per slide) and divided by the number
of cells per area.
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tify statistically significant difference in mRNA levels of CASP1 gene in lesional,
non-lesional and healthy control skin. Thus we were able to detect an activation of
CASP1 only using extra level of information, i.e. results of analysis immunoflu-
orescence microscopy data, that would not be possible from gene expression data
alone.
The combined results from qRT-PCR and fluorescent microscopy analysis strongly
suggest the increased activation of innate immunity in psoriatic lesions. The com-
bination of these results in multi-staged analysis with the signs of innate immunity
activation from other data sources provides the evidence for the autoinflammatory
disease pathogenesis.
5.3. Protein concentration in plasma provide extra information
about systemic inflammation
To study the signs of systemic inflammation further we measured the concen-
tration of several cytokines and chemokines (IL-17A, IL-6, TNF-α , IL-1Ra and
CXCL8) in plasma samples of psoriasis patients and healthy individuals. These
proteins are involved in cell to cell communication in immune responses. Us-
ing Wilcoxon rank-sum test (Section 3.2.7) we detected that a concentration of
a group of these proteins in psoriasis patients were elevated compared to con-
trol individuals. The results were consistent with the differential gene expression
analysis.
5.4. Linking the experimental data to the patient phenotype
Additionally, in our study we aimed to find gene expression and plasma protein
signatures for different phenotypic features of psoriasis. Comparisons of the se-
lected phenotypes in skin and plasma samples were performed using multi-factor
ANOVA (Section 3.2.5), followed by Tukey’s honest significant difference test to
find the groups that are significantly different from each other.
Gene expression in the psoriatic lesions, with an exception of TNFA gene, did
not exhibit any statistically significant change in patients with different pheno-
types. We identified a difference in expression levels of TNFA gene in patients
with psoriatic arthritis. At the same time gene expression in non-lesional skin was
more variable in psoriasis phenotypes. We managed to identify genes that were
connected to the severity of the disease, nail involvement, duration of the disease
and psoriatic arthritis. This way we showed that not only lesional skin but also
the non-lesional skin reveals signs of inflammation that are associated with the
variable clinical features of psoriasis. These clinical features constituted patient
phenotypes in our study.
The analysis of protein concentrations in plasma in psoriasis patients with sev-
eral phenotypes showed that the signs of systemic inflammation increased with
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the severity of the disease as it was linked to increased levels of IL-17A. Addi-
tionally, analysis revealed that IL-6 is associated with sporadic form of psoriasis
and is involved in the pathogenesis of the psoriatic arthritis.
5.5. Analysis of cell populations reveal the signs of premature
senescence in psoriasis
Sustained inflammation is believed to have similar damaging effects on the im-
mune cells, as observed during inflammageing, a chronic inflammation that in-
volves the up-regulation of the inflammatory response with age [263, 264].
We studied the changes in the T cells subpopulations in the psoriasis patients
and healthy control individuals using flow-cytometric immunophenotyping. We
compared the proportions of subpopulations in healthy and disease samples using
Wilcoxon rank-sum test (Section 3.2.7). We found that among innate-like virtual
memory CD8+ T cells the terminally differentiated or senescent T cells had higher
proportions in psoriasis patients similarly to the accumulation of these cells in
aged individuals [265].
Also as the long-term consequences of systemic inflammation on circulating
immune cells are not known in psoriasis patients, we studied T cell subpopula-
tions in patients with different disease duration. We carried out the comparison
of phenotypes using ANOVA followed by Tukey’s honest significant difference
test (Section 3.2.5). We identified a statistically significantly higher proportion of
terminally differentiated or senescent CD8+ T cells in patients with longer disease
duration.
These findings suggest premature immunosenescence, a decline of the immune
system with age advancement, occurring during disease. It is associated with
the implications to the psoriasis comordibidities such as several cancers [244].
As immunosenescence is generally associated with the increased risks of cancer
development [266,267], premature immunosenescence can play an important role
in the inability to resist cancers in psoriasis patients.
This finding suggests that chronic inflammation together with the sustained in-
nate receptor signalling drives premature immunosenescence in psoriasis patients,
which may have implications on the health status of the patients.
5.6. Summary and impact
Integrated analysis of biological data types such as transcriptomics, proteomics,
cell populations and clinical data about the patients allowed us to study the disease
pathogenesis from different angles and obtain more systematic view on the inflam-
matory processes in the disease. Data integration allowed to identify an activity
of the important regulators of innate immunity, signs of systemic inflammation
increase in several phenotypes associated with the severity of the disease, and the
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signs of premature senescence in psoriasis patients. The results of the study sup-
port the autoinflammatory hypothesis of the disease pathogenesis. These findings
would not be possible to obtain by analysing individual experimental data types
alone.
5.7. Contribution
My contribution to this project included statistical data analysis, data visualiza-
tion and writing statistical methods part in the manuscript. I performed gene
expression data analysis including preprocessing with filtering and imputation,
hierarchical clustering, PCA and differential expression analysis. Additionally,
I performed the comparison of the fluorescent intensities, comparison of the se-
lected patients’ phenotypes in skin, plasma samples and T cells subpopulations.
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6. IMPROVING DEVELOPMENTAL TOXICITY
TESTING STRATEGIES USING DATA INTEGRATION
(PUBLICATION III, IV)
Toxicity testing is the process of defining harmful effects of the substances for the
living organisms. One of its applications is safety assessment of drugs or other
chemicals for early development of a human organism.
In this chapter we describe the multi-staged integrative data analysis approach
and demonstrate how current testing strategies in toxicology can benefit from its
application. The approach of combining multiple data sources and the correspond-
ing analysis methods would possibly allow to identify key events in adverse out-
come pathways (Section 2.2.3.1) related to the action of toxic compounds and
define associated biomarkers [146, 268].
To address the problems stated above we investigated four groups of toxic com-
pounds: heavy metals, pesticides, polychlorinated biphenyls (PCBs) and histone
deacetylase inhibitors (HDACi).
The aims of this study were to investigate the following:
• whether the combination of transcritomics data with other data types would
provide information related to the toxicants mode of action (MoA) and as-
sociated adverse outcome pathways;
• whether the same resulting action of structurally diverse toxicants, i.e. met-
als, pesticides, HDAC inhibitors, is characterized by unified transcriptional
changes;
• whether patterns of transcriptional changes would reflect compound group-
ing;
• whether the analysis of a small group of migration-related transcripts would
allow to classify the compounds according to their MoA.
For the reader’s easier understanding of the data origins, their biological mean-
ing and applied statistical methods used in this study, we provided their detailed
description in Chapters 2-3.
In study III we have addressed the impact of the toxic chemicals on one of
the essential biological processes during normal human early development - the
ability of NCC to migrate correctly to different parts of the fetus where they dif-
ferentiate to various tissues, e.g. bones, neurons, etc. [269]. The workflow of
multi-staged integration for this study is outlined on the Figure 27.
The disturbance of neural crest functioning during early development can lead
to severe birth defects [270]. Several chemical compounds are known to disturb
the NCC migration process, i.e. NCC motility, causing developmental defects
[271, 272]. The harmful action of the chemical can be assessed by measuring
the cells ability to migrate using migration of neural crest cell assays (Section
2.2.1.7). The negative effect of a compound is defined as decreased or lack of
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Figure 27. Data integration in the analysis of toxic compound disturbing the migration
of NCC and their MoA. Individual data types were analysed separately using appropriate
statistical methods implemented in R language [254].
cellular migration after treating the cells with the compound.
However, MINC functional assay is a "black box" approach that allows us to
observe only the endpoint of the effect, i.e. if the cell motility was disturbed or not,
without understanding how it was achieved. By using only the functional assay
we are not able to judge about the mechanistic mode of action of the compound
and to understand how it disrupts the migration pathway. Some pathways were
identified to be important for the NCC migration. However, it is not clear which
of them are affected by toxicants and whether all toxicants have effect on the
specific group(s) of pathways.
One way to connect the final adverse outcome, e.g. disturbed NCC migration,
to the intermediate changes inside the cell is to understand the effect of toxic com-
pounds on the expression of the related genes. The possible outcome could be that
toxic compounds leading to the same effect cause similar changes. Alternatively,
each toxicant may trigger its own particular set of gene expression changes. In this
scenario different changes eventually lead to the same end result. In practice it has
been shown that several toxicity pathways may lead to the same end result [273].
Therefore the final outcome could be linked to different gene expression signa-
tures. This way toxicants sharing a mode of action would trigger similar changes
in the expression of relevant genes.
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6.1. Grouping toxic compounds by their transcriptional
signatures
In this study we first identified diverse toxicants that disturb the migration of NCC
in the MINC assay (MINC assay is described in Section 2.2.1.7). Then we iden-
tified transcriptional changes triggered by these toxicants in 35 migration-related
genes using qRT-PCR measuring technology (Section 2.2.1.4).
Grouping of toxicants according to their gene expression profiles using hierar-
chical clustering and PCA (Figure 28) identified the group of HDAC inhibitors as
previously unrecognized drug class affecting NCC migration.
Figure 28. The grouping of toxic compounds based on the results of PCA (figure is
adapted from Dreser et al. [274]). Projections of the individual experiments to the two-
dimensional planes reflect separation by the corresponding PCs.
This analysis showed that similar gene expression patterns of HDACi com-
pounds distinguished them from other migration inhibitors. We also demonstrated
that a group of PCBs and triazoles could be identified by distinct gene expression
signatures. Our study showed that a well-known drug for treating epilepsy and
bipolar disease, valproic acid, disrupts the NCC migration through the mecha-
nisms of histone deacetylase inhibition. To characterize the mechanisms of the
intermediate changes in the cell we identified potentially involved intermediate
pathways associated with the toxicants and their impact on the NCC migration.
We used k-means clustering to find the co-regulated genes and performed pathway
analysis of each cluster (Figure 29).
The results of the analysis demonstrated that HDACi group represents a new
group of toxicants with the effects on neural crest during development.
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Figure 29. Pathway analysis of migration-related clustered genes (figure is adapted from
Dreser et al. [274]). (A) k-means clustering of gene expression profiles over individual
compounds. Mean expression levels of the genes in each cluster are scaled (z-score) and
color-coded. Dark red and blue colors indicate high and low levels of expression corre-
spondingly. Expression profiles are hierarchically clustered using Euclidean distance and
average linkage. The genes of each cluster are shown. (B) For each cluster its contribution
in migration related processes is shown in separate window.
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6.2. Classification of the compounds
Additionally, to our analysis we built LDA-based statistical model for compounds
classification. This model allows the classification of the toxicants based on the
small number of genes. The application of the model on the given data set revealed
the compounds belonging to HDACi group being largely separated from the rest
of the toxicants. The developed model can help to assign unknown individual
compounds to the known toxicants and identify their mode of action.
6.3. Modeling neurodevelopmental defects caused by HDACi
Currently only limited amount of human data is available about how early devel-
opment is affected by chemicals. The mode of action of such chemicals can be
studied by mimicking the neurodifferentiation in vitro.
In the study IV we have investigated effects of HDACi group of toxic com-
pounds on early neurodifferentiation (Figure 30). We have studied the mecha-
nisms of action of these drugs including trichostatin A (TSA) valproic acid (VPA).
Valproic acid is an anti-epileptic drug that can cause several pathologies related to
early neurodifferentiation, such as fetal valproate syndrome (FVS) characterized
by neural tube defects during development. Due to the fact that effects of HDACi
are not well characterized in human cells, we have initiated this study to model
the disturbed neural development triggered by HDACi using multi-staged data
integration. Our goal was to identify a set of marker genes that would allow char-
acterization of drug-induced effects such as present in VFS using various data.
Additionally, we aimed to distinguish between short-term and long-term tran-
scriptional changes, triggered as a result of disturbed neurodevelopment caused
by HDACi. To answer these questions early neural differentiation was performed
from human embryonic stem cells towards neural lineage over 10 days. The pro-
longed drug-induced effects were studies after drugs were washed out for 1-2
days.
We have integrated the results of differential expression analysis using linear
models (Section 3.2.6) of gene expression microarray data (Section 2.2.1.3), PCA
(Section 3.2.1) and gene functional enrichment analysis (Section 3.2.9) of the col-
lected data during normal development and after the treatment with compounds.
PCA of gene expression of untreated cells and cells treated with HDACi revealed
that the strongest disturbance of differentiation was observed after toxicants ex-
posure during early neural fate decision, i.e. during the period of day 0 to day
6. PCA plot revealed a group of samples treated with HDACi were separated
from samples undergo normal neurodifferentiation. Differential expression anal-
ysis of microarray data showed that 2500 genes were altered after the treatments
with HDACi. Further characterization of the differentially expressed genes was
performed using functional enrichment analysis. We have identified statistically
significantly over-represented GO terms related to biological processes associ-
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ated with neuronal development, e.g. "nervous system development" and "central
nervous system development", "neurogenesis", etc., in genes down-regulated af-
ter treatment with HDACi. In the enrichment analysis results of up-regulated
genes we have observed terms such as "anatomical structure morphogenesis" and
"anatomical structure development". The results of PCA and functional charac-
terization of differentially expressed genes showed that new population of cells
emerged after the treatment with HDACi.
Combination of the individual results
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Figure 30. Data integration in the analysis of drug toxicity in early neurodifferentiation.
To investigate mechanisms of HDACi further, genes down-regulated by HDACi
were compared with genes that were identified in mouse-knockout study resulting
in neural tube defects. This combination of gene lists from our study and mouse
resulted in the 14 potential candidates that might be associated with human neu-
rodevelopmental defects.
As the next step of data integration we performed additional analysis of marker
genes to compare the similarity of VPA and TSA MoA. Altered expression of
these genes indicate disturbed neurodevelopment due to chemical-induced devel-
opmental neurotoxoicity. We performed differential expression analysis of qRT-
PCR data and additionally analysed immunofluorescence imaging data of well-
known neural marker PAX6. We have observed fully reproduced effects of VPA
by TSA. Further investigation of HDACi MoA with respect of effects on histone
modifications revealed that they can affect key differentiation factors indirectly by
affecting histone code in their promoter region.
Taking to account individual results, we have characterized the HDACi short-
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term and long-term effects on human cells. Study results suggested that long-
term transcriptional effects of HDACi differed from those found in short-term
studies, as they reflected altered neurodifferentiation due to secondary changes of
the histone code for key transcription factors.
6.4. Summary and impact
The findings suggest that the combination of gene expression data with phenotypic
functional cell-based assays, information about pathways related to neurodiffer-
entiation and information from Gene Ontology characterizing gene functions, can
improve the interpretation of the toxicity testing results. We showed that toxicants
sharing a mode of action trigger similar changes of intermediate cellular markers.
These findings allow detection of key events of adverse outcome pathways and
definition of biomarkers. Additionally, proposed classification strategy can be ap-
plied to identify mode of action of the unknown toxic compounds. The usefulness
of the proposed approach is demonstrated by the confirmation of HDACi group of
compounds as neural crest toxicants.
6.5. Contribution
In the study III I performed data analysis using PCA, k-means and hierarchical
clustering to investigate if the individual toxic compounds can be grouped based
on their mode of action. I also built an LDA-based statistical model for the classifi-
cation of toxic compounds based on their transcriptional signatures. Additionally,
I prepared part of the figures and participated in the manuscript writing and edit-




The aim of this work was to demonstrate the conceptual pipelines for data inte-
gration of heterogeneous biological data using data science methods, and to show
how integrative data analysis provides more systematic view on the biological
processes, helping to discover new knowledge.
In this work we have established two groups of data integration strategies -
multi-staged and transformation-based that can be applied to various biological
questions. We have described appropriate integration approaches for three practi-
cal study set-ups. In the Chapters 4-6 we have demonstrated how knowledge about
biological processes can be enriched through combining experimental, computa-
tional and domain knowledge data using machine learning methods.
As a result of conducting this research, we have designed and implemented a
multi-staged analysis for toxicology study and disease pathogenesis study.
Integrated analysis of the experimental and clinical data, i.e. presented in
Chapter 5, provided an opportunity to understand psoriasis pathogenesis from
different angles and characterize the inflammatory processes during the disease
in a broader perspective. The results of the integrative analysis support the au-
toinflammatory hypothesis of the disease pathogenesis. The complex view on the
pathogenesis also indicated potential implications for patient care that have not
been attended previously.
The findings that we have presented in Chapter 6 suggest that the combination
of gene expression data with other various data types and combination of analysis
methods improves in vitro toxicity testing strategies. Additionally, the developed
classification model can be applied to identify the mode of action of the unknown
toxic compounds. The practical implications of the proposed approach is demon-
strated by the experimental confirmation of HDACi group of chemical compounds
as neural crest toxicants and investigation of its MoA in valproate syndrome, that
would not be detected by analysing just a single data type.
We have designed a transformation-based data integration approach to com-
bine diverse omics data sets related to Azlheimer’s disease (Chapter 4). This ap-
proach allowed to integrate experimental and computational data from various
sources into one heterogeneous network-based data set. Thus, we have gener-
ated a novel domain-relevant resource that researchers can incorporate into their
analysis. This integrated resource allows researchers to get a systematic view on
Alzheimer’s disease by going from SNP to protein level. Additionally, we have
applied state-of-the-art deep learning methods for heterogeneous graph structured
data. The findings that we have presented suggest that by utilizing rich graph
structure, GCN methods are able to uncover gene relation to the disease, that
would not be detected by just using gene biological information alone.
For the effective omics data integration one has to understand data origins and
the relations of one data type to another. In this work we summarized and de-
scribed individual experimental and computational data types, their origins, the
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way they relate to each other, and what we can learn from their combination.
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SUMMARY IN ESTONIAN
Mitmekesiste bioloogiliste andmete ühendamine ja analüüs
Tehnoloogia kiire areng koos eksperimentaalandmete madalama tootmiskuluku-
sega on viinud bioteadustes suure hulga andmete genereerimiseni. Peamisteks sel-
listeks valdkondadeks on erinevad „oomikad“ nagu näiteks proteoomika, genoo-
mika ja trankstriptoomika. Need erinevad valdkonnad võimaldavad uurida elus-
olendeid, bioloogilisi süsteeme ning haigusi erinevatest aspektidest. Saadud and-
meid talletatakse valdkonnaspetsiifilistes andmebaasides nagu näiteks ArrayExpress,
IntAct ja ANDI. Sellistes andmebaasides hoiustatakse näiteks geeniekspressioo-
niandmeid, proteiin-proteiin interaktsioone kui ka paljusid teisi bioloogilisi and-
meid. Taoliste andmete analüüs on võimaldanud saada väärtuslikku informatsioo-
ni nii erinevate bioloogiliste protsesside kohta, kui ka leida biomarkereid, mis
viitavad teatud patoloogilisele protsessile, iseloomustavad vastust ravimitele või
aitavad hinnata terapeutilise sekkumise edukust. On aga selge, et eraldi neid and-
meid analüüsides jääb tervikpilt nägemata. Selleks, et luua huvipakkuvast bioloo-
gilisest protsessist (näiteks haigusest) süstemaatiline arusaam, on vaja neid and-
mestikke kombineerida. See aga tõstatab küsimuse, kuidas on ikkagi neid erine-
vaid andmestikke mõistlik kombineerida. Üheks esimeseks sammuks võiks olla
usaldusväärsete ja mahukate haigusspetsiifiliste andmestike moodustamine. On
ka selge, et tuleb kindlustada, et andmed oleksid kvaliteetsed ning seetõttu on
väga oluline osa andmete eeltöötlemisel, mis kätkeb endas mitteusaldusväärse-
te andmete filtreerimist kui ka andmestike viimist vastavusse FAIR standarditele.
Antud andmestikke oleks võimalik nii kasutada uute hüpoteeside testimiseks kui
ka kombineerimiseks teiste andmetega. Üheks probleemiks on aga ka andmete
heterogeensus, nimelt andmeid on toodetud väga erinevates eksperimentaalsetes
tingimustes kui ka väga erinevate vahenditega ning pole selge, kuidas need suhes-
tuvad uuritava fenotüübiga (nt haigusega). Sellest ajendatult on hakatud arendama
andmeteaduspõhiseid meetodeid, et bioloogiliselt tähendusrikkalt kombineerida
olemasolevaid andmeid. Tihtilugu käib see läbi mitmetasemelise analüüsi, mis
siis aitab täpsemalt uuritavat bioloogilist protsessi kirjeldada.
Tänapäeval puudub ühtne ja standardne viis, kuidas bioloogilisi andmeid in-
tegreerida. Üldjuhul lähtutakse konkreetsetest saadavalolevates andmetest (ekspe-
rimentaalsed, arvutuslikud ja valdkonnaspetsiifilised), mis koos uuringudisainiga
määravad ära, millist andmeanalüüsi lähenemist tuleks kasutada. Käesolevad väi-
tekirjas oleme kasutanud kahte eri lähenemist, mis osaliselt põhinevat Ritchie jt
poolt välja pakutud. Antud väitekiri kirjeldab, kuidas neid metoodikaid rakenda-
da erinevate bioloogiliste küsimuste uurimiseks ning uute bioloogiliste teadmiste
omandamiseks. Need lähenemised põhinevad uuritava fenotüübi ja individuaal-
sete saadaval olevate andmestike omavahelistel seostes ning meie hinnangul on
need sobivad erinevate uuringudisainide puhul. Täpsemalt, need kaks gruppi on:
mitmetasemeline ja transformatsioonipõhine integreerimine. Mõlemad koosne-
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vad erinevatest andmeteaduse meetoditest, mis kombineerituna võimaldavad leida
andmestikus ka muidu raskesti leitavaid seoseid. Mitmetasemeline andmete integ-
reerimine tähendab, et andmestikud analüüsitakse eraldi ning seejärel kombinee-
ritakse tulemused, mille põhjal tehakse juba üldistusi lähtuvalt valdkonnaspetsii-
filistest teadmistest. Sõltuvalt uuritava tunnuse ja andmete vahelisest seose iseloo-
must võib rakendada seal erinevaid andmeteaduse metoodikaid. Nende hulka kuu-
luvad näiteks regressiooni ja klassifikatsiooni meetodid ,nagu näiteks lineaarsed
mudelid, juhumetsad (ingl. k. Random Forest), mitmesugused testid nagu näiteks
t-test ja mitteparameetriline Wilcoxon test, klasterdamismeetodid, nagu k-means.
Transformatsioonipõhine integreerimine kätkeb endas aga andmete transformat-
siooni vahepealseks vormiks, näiteks graafiks. Võrreldes mitmetasemelise analüü-
siga, kus kasutatakse andmemaatrikseid, on transformatsioonipõhine lähenemine
oluliselt kompleksem. Seal kasutatakse heterogeenseid graafe, milles tipud ja ser-
vad on kirjeldatud läbi erinevate bioloogiliste muutujate.
Masinõppe-põhised meetodid on juba bioteadustes laialt levinud, võimalda-
des ennustada bioloogilisi väärtusi tegemata tugevaid eeldusi täpsete bioloogiliste
mehhanismide kohta. Sel juhul on muidugi erilisel kohal nii bioloogiliste tunnuste
valik ning nende disain, mille edukal valikul on võimalik saada täpseid mudeleid.
Klassikaliste masinõppe meetodite rakendamine graafianalüüsis on keeruline ku-
na need meetodid vajavad tihti käsitsi kombineeritud tunnuseid, on piiratud paind-
likkusega ning arvutuslikult kulukad. Viimastel aastatel on ka populaarust kogu-
nud süvaõppe (ingl. k. deep learning), mida rakendatakse edukalt piltide, teksti
ja videote analüüsis. Sellised mudelite puhul pole enam tunnuste disain vajalik,
kuna neid eraldatakse automaatselt. Kuid ka neid meetodeid ei saa otse graafidel
rakendada näiteks kuna graafi tipud pole järjestatud. Kuid graafide jaoks on disai-
nitud eraldi suvaõppemeetodid, mis on tuntud kui graafi konvolutsioonilised te-
hisnärvivõrgud (ingl. k. graph convolutional networks(GCN)). GCN-id suudavad
efektiivselt ära kasutada graafide struktuuri ning tippude vahelist informatsiooni.
Käesolevad väitekirjas näitame läbi praktiliste probleemide lahendamise, kuidas
integreerida ja analüüsida heterogeenseid bioloogilisi andmeid kolmes valdkon-
nas: immunoloogias, toksikoloogias ja Alzheimeri tõve uuringutes. Teine peatükk
keskendub erinevatele oomikaandmetele ning eksperimentidele, kuidas neid too-
detakse. Liskas kirjeldame selles peatükis, kuidas on üks andmetüüp seotud tei-
sega. Kolmandas peatükis me tutvustame eelmainitud kahte andmete integreeri-
mise lähenemist – transformatsioonipõhist ja mitmetasemelist. Seejärel me an-
name ülevaate andmeteaduse metoodikatest, mida me kasutasime andmeanalüüsi
juures, alates hüpoteeside testimisest kuni juhendatud õppe ja graafide spetsiifilise
süvaõppeni. Järgnevates peatükkides (4-6), me näitame, kuidas integratsioonipõ-
hine analüüs võimaldab paremini aru saada bioloogilistes protsessidest järgmistes
kolmes valdkonnas: Alzheimeri tõbi, toksilisuse testimine ja immunoloogia.
Täpsemalt, neljandas peatükis, mis põhineb publikatsioonil I, kirjeldame and-
mete integreerimist rakendatuna Alzheimeri tõve uurimisele. Alzheimeri tõbi on
vanusega seotud neurodegeneratiivne haigus, mis progresseerub vanusega ning
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viib surmani. Alzheimeri tõve sümptomite vähendamiseks kasutatakse mitmeid
ravimeid, kuid ükski olemasolev ravi meetod ei saa muuta haiguse aluseks ole-
vaid protsesse. Me kasutame transformatsioonipõhist andmete integreerimist ja
kirjeldame uudset heterogeenset graafil põhinevat andmestikku Alzheimeri tõve
jaoks (HENA). HENA koosneb 64 andmestikust ning kuuest eri andmetüübist,
mis pärinevad üheksast eksperimendist. Sinna kuuluvad andmed valk-valk inte-
raktsioonide, geeni koekspressiooni, epistaasi, positiivse selektsiooni, aju eri re-
gioonide geeniekspressiooni kohta, kui ka ülegenoomsetest assotsiatsiooni uurin-
gutest (GWAS) pärinevad andmed. HENA võimaldab teadlastel kasutada neid
andmeid nii Alzheimeri tõve uurimiseks kui ka oma mudelite testimiseks. Me
ka näitame, kuidas kasutada HENA-t, et leida haigusega seotud geene. Viiendas
peatükis (põhineb publikatsioon II-l), me näitame, kuidas läbi mitmeetapilise and-
meintegratsiooni saab uurida immuunhaiguste mehhanisme. Uuritavaks haiguseks
on psoriaas, mis on krooniline põletikuline haigus ning mille tunnuseks on löö-
beelemendid kehal. Haiguse mehhanismid pole veel selged. Et saada haigusest
paremat selgust, me kombineerisime patsiendi verest ja nahast pärinevaid labo-
ratoorseid andmeid kliinilise infoga. Seejärel viisime individuaalsete analüüside
tulemused kokku kasutades lähtuvalt erialaspetsiifilistest teadmistest. Kuues pae-
tükk (mis põhineb publikatsioonidel III ja IV), on pühendatud toksilisuse testimise
strateegiate edasiarendusele. Seal me kasutame samuti mitmetasemelist andmete
integratsiooni. Toksilisuse testimine tähistab protsessi, mille käigus hinnatakse,
kas uuritavatel kemikaalidel esineb kahjulikke toimed organismile. See on vaja-
lik näiteks ravimite ohutuse hindamisel. Selles töös me identifitseerisime sarnase
toimemehhanismiga toksiliste ühendite rühmad. Lisaks me arendasime ka klassi-
fikatsioonimeetodi, mis võimaldab hinnata uute ühendite toksilisust.
Autori panused artiklite I-IV põhjal on järgmised:
1. Alzheimeri tõve, toksikoloogia ja immunoloogia valdkonnas andmestike
kogumine ja integreerimine (I-IV).
2. Integratsioonipõhise andmeanalüüsi läbiviimine nii Alzheimeri tõve, toksi-
koloogia kui ka immunoloogia valdkonnas (I-IV).
3. Graafil põhinevate konvolutsiooniliste tehisnärvivõrkude rakendamine suur-
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